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<ABSTRACT> 
 
 
The role of ASK1 in selective striatal lesion formation induced by 
neuronal injury 
 
 
Kyoung Joo Cho 
 
 
Department of Medical Science 
The Graduate School, Yonsei University  
 
(Directed by Professor Jong Eun Lee) 
 
 
Apoptosis signal-regulating kinase-1 (ASK1), an early signaling element in 
the cell death pathway, has been suggested to participate in the pathology of 
neurodegenerative diseases, which may be associated with environmental 
factors that impact the diseases. The systemic administration of 3-nitropropionic 
acid (3-NP) facilitates the development of selected striatal lesions and it remains 
unclear whether specific neurons are selectively targeted in 3-NP infused striatal 
degeneration. Although not entirely elucidated, the mechanisms of neurotoxicity 
induced by 3-NP have been shown to include the exhaustion of adenosine 
triphosphate, mitochondrial membrane depolarization, dysregulation of 
intracellular calcium homeostasis, calpain activation, and the release of 
pro-apoptotic proteins from mitochondria. The present study is to characterize 
the regulation of BDNF in each cortical and striatal subregion. This study 
investigates that mild and chronic exposure of mitochondrial toxin can 
modulate the C1q level both in cortex and striatum via regulation of TGF-beta 
2 
 
from astrocyte. Consequently we investigate how the BDNF is dominantly 
depleted in striatum, and eventually whether striatal lesion is established in 
involving in ASK1 pathway.  
The results of the present work show an alteration of ASK1 pathway 
molecules, TGF-beta, C1q level, and BDNF level as a final standard to striatal 
degeneration. By ASK1 down-regulation, improvement in each molecules 
containing behavioral impairment was evaluated in 3NP- infused mice and 
3-NP treated primary neuronal cells. We propose the hypothesis that (1) ASK1 
overexpression by systemic infusion of 3-NP promotes the formation of 
selective striatal lesions, and this occurs apart from just ROS generation. (2) 
ASK1 may differentially regulate C1q secretion level via active TGF-beta in 
each brain subregion of cortex and striatum, consequently involved in axon 
degeneration of corticostriatal projection neuron. When brain is mildly and 
chronically exposed to mitochondrial toxin, presynaptic neuron (in cortical 
neuron) degrades first, and then postsynaptic neuron of striatal MSN neuron 
withers as a consequence of it. 
Consolidating these results, we suggest that the increased ASK1 is linked to 
regulation of TGF-beta secreted in astrocytes, and differential C1q expression in 
neurons triggered by TGF-beta leads degradation of cortical projection and 
depletion of BDNF in striatal neuron in mice brains systemically infused with 
3-NP.  
 
 
 
 
---------------------------------------------------------------------------------------------------------- 
Key words : apoptosis signal-regulating kinase 1, 3-nitropropionic acid, Huntington’s 
disease, brain derived neurotrophic factor, siRNA, superoxide dismutase  
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PART I 
 
 
 
 
Inhibition of ASK1 reduces ER stress and nuclear huntingtin 
fragments in a mouse model of Huntington Disease 
 
4 
 
I. INTRODUCTION 
 
Accumulation of misfolded proteins within the endoplasmic reticulum (ER) 
lumen induces ER stress, which has been implicated in human diseases such as 
Alzheimer’s disease 1, Parkinson’s disease 2, and Huntington’s disease (HD) 3. 
HD is characterized clinically by chorea, psychiatric disturbances, and dementia, 
while it is characterized pathologically by neuronal inclusions as well as striatal 
and cortical neurodegeneration. The neurodegeneration is arisen from the loss 
of long projection neurons in the cortex and striatum 
4
. HD is inherited in an 
autosomal dominant manner, and is caused by the presence of an elongated 
polyglutamine (polyQ) tract (> 40) in the huntingtin (htt) gene 
5
. 
Htt fragments with pathogenic repeat lengths have been reported to 
co-localize with various molecular chaperones 
6,7
 and proteasome components 
and to impair the function of the ubiquitin-proteasome system (UPS) 
8
, resulting 
in ER stress 
9
. Apoptosis signal-regulating kinase 1 (Ask1) is reported to be 
involved in ER stress triggered by htt fragments, which results in neuronal cell 
death. ER stress activates Ask1 through the formation of the 
IRE1-TRAF2-Ask1 complex. Furthermore, the expanded polyQ portion of htt 
activates Ask1, and it has been shown conclusively that Ask1 is required for 
polyQ-induced neuronal cell death 
3,4,10,11
. Nevertheless, despite the numerous in 
vitro studies supporting a correlation between Ask1 and ER stress, it is not 
known whether the level of ER stress and Ask1 protein levels or activity are 
increased in vivo in HD transgenic (tg) animals. In HD, Ask1 is thought to be a 
modifier of htt at the gene level 
12
, a signal transducer at the protein level 
10
, and 
a cell death modulator at the post-translational level 
13
. It has also been 
suggested that the manifestation, progression, and outcome of HD may be 
affected by modifier genes and environmental factors that impact the disease’s 
5 
 
presentation 
12
.  
In this study, we investigated the role of Ask1 in the pathogenesis of HD 
transgenic (tg) mice. Specifically, we analyzed the expression of Ask1 and htt 
within the striatum and cortex along with ER stress in each region, and 
determined whether Ask1 interacts with htt fragments in vivo. Additionally, we 
assessed the levels of brain-derived neurotrophic factor (BDNF) in a 
region-specific manner, and examined the effects of inactivation of Ask1 on 
striatal atrophy and motor dysfunction. 
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II. MATERIALS AND METHODS 
 
1. Animal model 
In this study, 8-week and 12-week R6/2 HD male tg (The Jackson 
Laboratory, Bar Harbor, ME, U.S.A.), littermate wt mice were used. All 
procedures were performed in accordance
 
with the guidelines for the care and
 
use of laboratory animals (Yonsei University, Seoul, Korea), which are 
approved by the Association for Assessment and Accreditation of Laboratory 
Animal Care (AAALAC). Animals were anesthetized with 2.0% isoflurane
 
under 30% oxygen and 70% nitrous oxide using a vaporizer (VMC Anesthesia 
Machine, MDS matrix, Orchard Park, NY, U.S.A.). Rectal temperature was 
controlled at 370.5°C with a homeothermic blanket.  
 
2. Immunohistochemistry  
To determine the pattern of localization of htt (Epitomics, Burlingame, 
CA, U.S.A; 1C2, Chemicon, Bedford, MA, U.S.A.) and Ask1 (Santa Cruz 
Biotechnology, Santa Cruz, CA, U.S.A.), we performed immunofluorescent 
staining. After sacrificing the animals, their brains
 
were removed, postfixed o
vernight in 3.7% formaldehyde, and stored in 30% sucrose. After fixation, the 
brains were cut into coronal sections of 20 m thickness on a cryostat section 
and processed for immunohistochemistry. Fixed sections were incubated with 
the blocking solution as described previously 
14
 and incubated with a prim
ary antibody, rabbit polyclonal anti-htt antibody (1:100, Epitomics).
 
After 
washing, the sections were incubated with FITC-conjugated donkey anti-rabbit 
IgG (1:200, Jackson ImmunoResearch, West Grove, PA, USA). For 
counter-staining, the sections were incubated with propidum iodine (PI, 1:5000, 
Sigma, St. Louis, MO, U.S.A.). The stained tissue samples were washed and 
7 
 
mounted using Vectashield mounting medium (Vector Lab, Burlingame, CA, 
U.S.A.). These sections
 
were observed under a LSM510 confocal laser 
scanning microscope (Carl Zeiss, Thornwood, NY, U.S.A.).  
For immunofluorescent double-labeling with htt and Ask1, htt (1:100, 
Epitomics) immunohistochemistry was performed as described above, followed 
by incubation with Cy
TM
 3-conjugated donkey anti-rabbit IgG (1:200, Jackson 
ImmunoResearch). After washing, the sections were incubated with the 
blocking solution and reacted with goat anti-Ask1 antibody (1:100, Santa Cruz 
Biotechnology), followed by FITC-conjugated donkey anti-goat IgG (1:200, 
Jackson ImmunoResearch). The sections were then covered with a cover-slip 
and examined under a confocal microscope (Carl Zeiss). 
 
3. Western blot analysis and co-immunoprecipitation  
The expression levels of proteins were analyzed by western blotting. The 
cortex or striatum of dissected animal brains were lysed in lysis buffer (20 mM 
Hepes–KOH, pH 7.5, 250 mM sucrose, 10 mM KCl, 1.5 mM MgCl2, 1 mM 
EDTA, 1 mM EGTA, 0.5 mM PMSF, 0.1 mM sodium vanadate, and 0.1 mM 
proteinase inhibitor cocktail). The samples were homogenized by douncing with 
a Teflon homogenizer (Wheaton, Millville, NJ, U.S.A.) and centrifuged at 8,000 
g for 20 min at 4℃. The lysates were loaded onto SDS-polyacrylamide gels. 
After
 
migration, the proteins were electrotransfered onto a polyvinylidine
 
difluoride membrane (PVDF) (Millipore, Bedford, MA, U.S.A), which was 
blocked in
 
5% skim milk, incubated with primary antibodies; Ask1 (1:1000, 
Cell Signaling, Danvers, MA, U.S.A.), pAsk1 (1:1000, Cell Signaling), 1C2 
(1:5000, Chemicon, Bedford, MA, U.S.A.), htt (1:1000, Epitomics), or BDNF 
(1:500, Abchem, Cambridge, UK). After washing, blots were incubated with 
HRP-conjugated secondary antibodies
 
(1:5000, Roche Diagnostics, Indianapolis,
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IN, U.S.A.) and the bands were visualized with
 
an enhanced chemiluminescence 
reagent (Amersham Biosciences, Piscataway, NJ, U.S.A.). To separate the 
cytosolic and nuclear fractions of the proteins, each sample was homogenized 
briefly in lysis buffer and then spun down at 750 g for 10 minutes at 4ºC. The 
pellet containing the nuclear fraction was resuspended with lysis buffer. The 
resuspened solution was centrifuged at 16,000 g for 20 min at 4℃and the 
supernatant was used as the nuclear fraction. The supernatant obtained after 
centrifugation at 750 g for 10 minutes was then centrifuged at 10,000 g for 20 
min at 4℃, and the supernatant containing the cytosolic fraction was transferred 
to a new tube. This tube was centrifuged at 100,000 g for 1 hr at 4℃ and the 
supernatant obtained was designated the cytosol. 
The procedure for co-immunoprecipitation was performed as described 
previously with some modifications 
15
. The cortex and striatum were removed 
from mice brains, and prepared
 
in the same manner as for western blotting. The 
protein samples were incubated in a 50% slurry of protein A-sepharose 
(Amersham Biosciences), and this mixed sample was centrifuged at 12,000 g 
for 1 min at 4℃. The supernatant was incubated with 20 µl of protein 
A-sepharose for 2 hr at 4°C and then incubated with 2 µg of goat anti-Ask1 
antibody (1:1000; Santa Cruz Biotechnology) overnight at 4°C. The pellets 
were washed by centrifugation at 14,000 g for 3 min at 4℃. After centrifugation, 
the supernatant was immunoblotted with polyclonal rabbit anti-htt antibody 
(1:1000; Epitomics) and with mouse anti-Ask1 antibody as a control. 
 
4. RT-PCR Analysis  
Total RNA was isolated from the striatum and cortex of the mice. Total 
RNA (1 g) was reverse-transcribed and cDNA was synthesized using PCR. 
The primers used are shown in Table 1. PCR was performed as follows: initial 
9 
 
denaturation at 95°C for 10 min, amplification (30 cycles) for 30 sec at 95°C, 
30 sec at 60°C, and 30 sec at 72°C, and a final extension at 70°C for 10 min. To 
semi-quantify BDNF mRNA levels without performing real-time PCR, we 
performed the PCR reaction for different numbers of cycles (15, 20, 25, and 30 
cycles). RT-PCR products were visualized with a UV illuminator after 
electrophoresis on an agarose gel. 
 
5. Neutralization of Ask1 using an anti-Ask1-antibody 
To inactivate Ask1 for an extended period of time (several weeks), we 
used an Ask1 antibody raised against an epitope corresponding to amino acids 
at the C-terminus of the Ask1 protein. The antibody was added to the dried 
BioPORTER (Quiktease protein delivery kit, Sigma Aldrich) reagent and 
allowed to incubate at room temperature for 10 min according to the 
manufacturer’s protocol 16. The mixture of Ask1 antibody and BioPORTER was 
loaded into an osmotic reservoir. Mice were anesthetized as described above 
and placed in a stereotaxic apparatus. A micro-osmotic pump reservoir (Alzet, 
Cupertino, CA, U.S.A.) containing anti-Ask1 antibody (0.2 mg/ml in saline, 
Santa Cruz) was placed subcutaneously on the backs of the animals 
17
. A brain 
infusion cannula connected to the pump was positioned at the intra-striatum 
(anterial, 0.7 mm; lateral, 1.2 mm; and depth, -3.3 mm). As a control, rabbit IgG 
or pre-immune Ask1 antibody was infused in the same way. The infusion rate 
was 1.0 l/h and the pump infused the designated solution for 4 weeks into the 
brains of HD tg mice. After implantation of the osmotic pump at the age of 
8-weeks, the mice were sacrificed 4 weeks later 
18
. 
 
6. Rotarod test 
The motor function of model animals was assessed with a rotarod 
10 
 
apparatus (Ugo Basile North America Inc., Schwenksville, PA, U.S.A.), where 
the time a mouse was able to remain on the rod was measured at an accelerating 
speed from 4 to 40 rpm 
19
. Each mouse was trained for 5 min and the training 
session was followed by a 30 min rest period. Mice were then placed back on 
the rotarod for five trials of a maximum of 5 min at accelerating speed. Mice 
were evaluated for 3 consecutive days.  
 
7. Striatal lesion analysis 
Four weeks after Ask1 inhibition with antibody, animals were 
anesthetized and decapitated. Brains were frozen and cut on a cryostat into 20 
m sections from the anterior to the posterior at 500 m intervals. The sections 
were stained with cresyl violet and then scanned with an LAS1000 imaging 
densitometer (Fujifilm, Tokyo, Japan). Striatal atrophy was identified as a 
striatal region size with pallor or loss of cresyl violet staining. The area of the 
striata was measured using Sigmascan Pro (ver 6.0). 
 
8. Statistical analysis 
Data are expressed as mean ± SD.
 
The significance of differences among 
multiple groups was evaluated by ANOVA followed by Fisher's post hoc 
protected least-significant
 
difference test, while two groups were compared 
using unpaired t tests (StatView, version 5.01; SAS Institute Inc, Cary, NC).
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III. RESULTS 
 
1. Levels of ASK1 protein and ER stress are increased in HD mice 
In vitro studies in neuronal cell cultures have shown that Ask1 is involved 
in the pathogenesis of HD 
3
. In our western blot assay (Figure 1; n = 6 each), the 
amount of Ask1 protein was increased in HD mice compared to wt mice; 
furthermore, higher levels of Ask1 were detected in the cortex than in the 
striatum of both HD tg and wt mice. Ask1 protein in the cortex was mostly 
present in the nuclear fraction, and barely detectable in the cytosol; similarly, in 
the striatum, more Ask1 protein was present in the nuclear fraction than the 
cytosolic fraction (Figure 1; n = 5). 
ER stress was evaluated by assessing the level of CHOP expression using 
RT-PCR (Figure 2; n = 5 each). Levels of CHOP, a member of the C/EBP 
family of bZIP transcription factors and an indicator of ER stress, were higher 
in HD than wt mice. Specifically, CHOP expression was higher in the cortex 
than in the striatum, which correlates with protein expression level of Ask1.  
We confirmed the pattern and cellular localization of fragmented htt in 
HD mice by immunohistochemistry (Figure 2; n = 5 each). High-magnification 
imaging of htt immunoreactive neurons in the cortex and striatum revealed a 
perinuclear pattern of fragmented htt staining. The striatal neurons of HD mice 
stained relatively weakly for htt, which may reflect the lower level of htt 
expression in the striatum compared with cortical neurons. When we 
double-stained for both Ask1 and htt, we found that Ask1 and htt fragments 
colocalized in the cytsol in both the cortex and striatum (Figure 2; n = 3 each).  
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Figure 1. Expression of Ask1 in HD transgenic mice (tg) and HD littermates 
(wt). (A) Western blot analysis of Ask1 protein in HD and wt mice 
demonstrates that the Ask1 protein is expressed in cortical and striatal regions, 
respectively. (B) Ask1 protein is expressed at higher levels in the nuclear than in 
the cytosolic fraction; this is especially noticeable in the cortex. 
A B 
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Figure 2. ER stress and expression pattern of Ask1 in HD transgenic mice 
(tg) and HD littermates (wt). (A) CHOP mRNA expression, a marker of ER 
stress, was evaluated in the cortex and striatum of HD and wt mice using 
RT-PCR. CHOP mRNA was highly expressed in the cortex of HD mice. (B) 
immunohistochemical staining of htt. Htt-positive cells show a perinuclear 
staining pattern in the cytosol of both the cortex and striatum of HD mice. (C) 
Double immunohistochemistry of Ask1 and htt fragments demonstrates that the 
two molecules are co-localized.  
Scale bar = 10 m; cor, cortex; str, striatum; *p < 0.01 
A 
B C 
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2. ASK1 interacts with htt fragments and aids in the translocation of htt  
We inhibited Ask1 activity for 4 weeks using an anti-Ask1 antibody, and 
confirmed that HD mice brains exhibited diminished Ask1 activity under these 
conditions (Figure 3A; n = 5 each). Infusion of the Ask1 antibody into the 
striatum of HD mice resulted in a reduction of CHOP expression in both of 
cortex and striatum (Figure 3B; n = 5 each). 
Co-immunoprecipitation and double-immunohistochemistry experiments 
revealed that inactivated Ask1 bound to htt fragments, and this occurred to a 
greater extent in the cortex than in the striatum (Figure 4; n = 4 each). The 
complex of two molecules was mostly shown in the cortex moreover the 
combined complex was detected in the cytosol than in the nucleus of the cortex. 
(Figure 4; n = 3 each). Double immunohistochemistry of Ask1 and htt 
confirmed that inactivated Ask1 and htt fragments co-localized in the cytosol of 
cortical neurons (Figure 4; n = 4).  
15 
 
 
 
 
 
Figure 3. The effect of inhibition of Ask1 on the levels of ER stress and htt 
fragments in HD. (A) Co-immunoprecipitation of Ask1 and pAsk1 (Thr 845) 
determined whether Ask1 was inhibited effectively in Ask1 antibody-treated 
mice. The amount of pAsk1 is significantly reduced in Ask1 antibody-treated 
HD mice. (B) RT-PCR results for CHOP show that ER stress is decreased in 
both the cortex and striatum of Ask1 antibody-treated HD mice. *p < 0.01 
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Figure 4. The effect of neurtralizing Ask1 on htt fragments localiziation in 
HD. (A) Inactivated Ask1 interacts with htt fragments. Co-immunoprecipitation 
of Ask1 and htt fragments in the cortex and striatum of Ask1 antibody-treated 
HD and IgG/preimmune antibody-treated HD mice. (B) 
Co-immunoprecipitation of Ask1 and htt fragments was performed in the 
subcellular fraction in the both of cortex and striatum. More htt immunoreactive 
products are present in the cytosol fraction than in the nuclear fraction of the 
cortex in Ask1 antibody-treated HD mice. (C) Cells double positive for Ask1 
and htt are detected in the cytosol of the cortical region of Ask1 
antibody-treated HD mice.  
Scale bar = 5 m. (-), without antibody; cor, cortex; str, striatum; *p < 0.01 
A 
B C 
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3. Inhibition of ASK1 facilitates BDNF transport to the striatum and improves 
motor dysfunction  
BDNF mRNA levels were shown to differ between different brain 
regions of HD mice, including the cortex and striatum (Figure 5; n = 5 each). 
There were more BDNF transcripts present in the cortex than in the striatum of 
wt mice, whereas BDNF mRNA levels in the cortex of HD mice were 
significantly reduced compared to the level of striatal BDNF mRNA in wt mice. 
Western blotting of BDNF revealed that inhibition of Ask1 significantly 
prohibit the reduction of BDNF protein levels in the striatum of HD mice 
(Figure 5; n = 7 each). Although levels of BDNF protein increased as a result of 
Ask1 inhibition, there were no significant changes in BDNF mRNA levels 
between Ask1-inhibited HD (anti-Ask1 treated HD, A) and vehicle-treated HD 
mice (rabbit IgG treated HD, I) (Figure 5; n = 5 each). Thus, the increase in 
BDNF protein as a result of the inhibition of Ask1 was not due to an increase in 
the amount of BDNF transcript. 
We next evaluated motor function in HD mice at 12 weeks of age, at 
which stage brain Ask1 had been inhibited for 4 weeks. There was significant 
performance impairment in HD mice at 12 weeks of age, indicated by the 
reduced times these mice were able to stay on the rotarod compared to wt mice 
(Figure 6; n = 4 each). HD mice treated with Ask1 antibody, however, showed 
improved motor performance compared to preimmune antibody-treated HD 
mice. We also assessed the changes in striatal atrophy in Ask1 antibody-treated 
HD mice by measuring the size of the striatal region (Figure 6, n = 3 each). The 
striatum was larger in the Ask1 antibody-treated HD mice than naïve HD mice 
or preimmune antibody-treated HD mice (p = 0.014). 
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Figure 5. The effect of inhibition of Ask1 on expression of BDNF. BDNF 
mRNA expression was reduced in both the cortex and striatum of HD mice, 
whereas BDNF mRNA is expressed at a high level in the cortex of wt mice. 
Western blot analysis of BDNF protein demonstrates that the level of BDNF 
expression in the HD mice treated with Ask1 antibody (anti-Ask1) or 
IgG/preimmune antibody (IgG) increased in the striatum of Ask1 
antibody-treated HD mice; BDNF mRNA levels are not significantly different 
between Ask1 antibody-treated HD (anti-Ask1, A) and IgG/preimmune 
antibody-treated HD mice (IgG, I) 
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Figure 6. The effect of inhibition of Ask1 on expression of motor 
dysfunction. (A) Motor function was evaluated as the amount of time spent on 
the rotarod. HD mice were not able to remain on the rod for long periods of 
time, but Ask1-inhibited HD mice remained on the rotarod longer than 
vehicle-treated mice. There was no significant difference in motor performance 
between naive HD mice and vehicle-treated HD mice. cor, cortex; str, striatum; 
*p < 0.01. (B) Inhibition of Ask1 prevents striatal atrophy. Representative 
photographs of brain sections from Ask1 antibody-treated or IgG/preimmune 
antibody-treated HD mice ; Sizes of the striatal area and ventricle in Ask1 
antibody-treated HD mice (anti-Ask1) and IgG/preimmune antibody-treated HD 
mice (IgG). Scale bar = 500 m; *p = 0.014.  
 
 
 
 
A B 
20 
 
IV. DISCUSSION 
In this study, we presented two novel findings suggesting that increased 
Ask1 may play a critical role in HD progression in mice. First, we showed for 
the first time in vivo that the level of Ask1 protein is increased in HD (R6/2) 
mice, as is ER stress. Second, we demonstrated that inhibition of Ask1 prevents 
the translocation of htt fragments and improves motor dysfunction in mice, 
suggesting that Ask1 may be closely correlated with disease development in HD 
mice.  
Our findings indicate that Ask1 is an element in ER stress-triggered 
neuronal cell death in a HD animal model (Figure 1). This finding is consistent 
with a study performed in a cell culture system that showed that Ask1 mediates 
proteasome dysfunction and ER stress-induced neuronal cell death by 
neuropathological alterations in polyQ disease 
3
. Moreover, the levels of Ask1 
protein and CHOP transcripts were greater in the cortex than the striatum of HD 
mice (Figure 1). Our study showed that the level of Ask1 protein was increased 
in the cortex and striatum of HD mice (Figure 1). Based on our previous study 
of Ask1 
14
, phosphorylation of Ask1 is required for its activation, but if 
insufficient Ask1 protein is present, cell death may not be initiated. Normal htt 
is balanced with the pro-apoptotic role of the N-terminal mutant htt fragments 
20
. 
However, expansion of the htt fragments could disrupt this balance because of 
the sustained presence of htt fragments. In HD, loss of intact htt along with 
accumulation of htt fragments may move the cell towards a toxic state 
21
, which 
is known to damage corticostriatal projection neurons thereby reducing growth 
factors such as BDNF in the cortex. Finally, reduced BDNF transport from the 
cortex to the striatum may result in the death of striatal cells and behavioral 
abnormalities 
5
. In the present work, we demonstrated that intact htt was 
reduced to a greater extent in HD than in wt mice, and that levels of htt are 
21 
 
lower in the striatum than in the cortex of HD mice (Figure 2), suggesting that 
htt fragmentation may occur to a greater extent in the striatum of HD mice. 
Furthermore, the vast majority of htt fragments was detected in the cytoplasm 
(Figure 2), consistent with previous reports that cytoplasmic htt cleavage 
precedes nuclear uptake 
20,21
. 
Ask1 activity, as assessed by the amount of pAsk1 (Thr845) present, was 
effectively inhibited in both the cortex and striatum of the Ask-1 
antibody-treated group compared to the control group (Figure 3). Because Ask1 
antibody was infused in the striatum, Ask1 activity was scarcely detected in the 
striatal fraction in contrast to the cortical fraction. When Ask1 activity was 
inhibited (Figure 3), CHOP induction decreased significantly. Inactivated Ask1 
binding to htt fragments was mainly detected in the cytosolic fraction of cortical 
cells, as shown by the immunoprecipitation and double-immunohistochemistry 
experiments (Figure 4). Larger htt fragment do not readily enter the nucleus 
22
, 
and the translocation of htt fragments to the nucleus is associated with increased 
htt toxicity in vitro and neuropathology in vivo 
20
. Because caspases interact 
with htt and produce cytotoxic htt fragments, the interaction of caspases and htt 
amplifies caspase activation and initiates the caspase cascade in the brains of 
patients with HD 
20,22
. We speculate that Ask1 may recruit caspases thereby 
facilitating htt fragmentation. In future studies, we plan to investigate this 
hypothesis. Alternatively, Ask1 in the normal state may act as a type of 
chaperone and help the smaller htt fragments enter the nucleus, but when 
inhibited, might bind to htt fragments in the cytosol and hinder the translocation 
of htt fragments into the nucleus. Based on our results, we suggest that Ask1 is a 
key modulator of cellular signal transduction in R6/2 HD mice. Ask1 has a dual 
role: it is activated by various harmful stimuli and simultaneously activates or 
binds to other cellular molecules. We suggest that Ask1 is activated by ER stress 
22 
 
and that active Ask1 interacts with htt fragments, allowing them to translocate 
into the nucleus more efficiently. This interaction may amplify ER stress and 
may contribute to an htt toxicity feedback loop. This interaction may be one of 
the explanations why ER stress was reduced in Ask1 antibody-treated HD mice. 
We speculate that Ask1 positively regulates ER stress rather than simply 
respond to the ER stress signal. Under the condition of continuous ER stress, 
ER stress-induced neuronal cell death could be suppressed by BDNF-mediated 
neuroprotection 
23,24
. Prevention of BDNF protein reduction by inhibition of 
Ask1 could be inferred to suppress CHOP expression, which may supply 
another explanation for positive regulating role of Ask1 in CHOP. 
In HD pathogenesis, the hypothesis that dysfunction of the corticostriatal 
pathway may contribute to the onset of HD has been supported by the 
observation that BDNF is expressed in cortical neurons and delivered to striatal 
neurons 
25
. BDNF co-localizes with htt in cortical neurons that project to the 
striatum 
5
. In this study, when Ask1 was inactivated in the striatum, the levels of 
BDNF protein in the cortex increased compared to preimmune antibody-treated 
HD mice, although there was no difference in the expression level of BDNF 
transcripts. These findings imply that inactivated Ask1 modifies the levels of 
BDNF protein at the post-translational level. Because cortex-specific deletion of 
BDNF is known to elicit progressive striatal degeneration in mice 
25
, BDNF 
reduction is expected to contribute to striatal pathogenesis in HD. Although 
striatal toxicity caused by htt fragments alone can not explain progressive 
locomotor deficits 
26
, our rotarod test results demonstrate that inhibition of Ask1 
activity in the striatum can alleviate motor dysfunction symptoms in HD mice 
(Figure 6). Along with the improvement in motor dysfunction, striatal atrophy 
was decreased in Ask1 antibody-treated HD mice compared to that in naïve HD 
and IgG/preimmune antibody-treated HD mice (Figure 6).  
23 
 
V. CONCLUSION 
 
In this study, we demonstrated that ASK1 was involved in the 
translocation of small htt fragments into the nucleus rather than htt cleavage. 
Increased levels of Ask1 may interact with htt fragments and subsequently 
induce ER stress. ER stress can be diminished by inhibiting Ask1, resulting in 
prevention of BDNF depletion in the striatum and an improvement in 
behavioral and anatomical abnormalities. Therefore, regulating the amount and 
activity of Ask1 protein are promising novel treatment strategies for HD.  
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PART II 
 
 
 
 
Apoptosis signal-regulating kinase-1 aggravates ROS-mediated 
striatal degeneration in 3-nitropropionic acid-infused mice 
25 
 
I. INTRODUCTION 
 
The compound3-nitropropionic acid (3-NP) produces selective striatal 
lesions in animal models 
27
. Although not entirely elucidated, the mechanisms 
of neurotoxicity induced by 3-NP have been shown to include the exhaustion of 
adenosine triphosphate, mitochondrial membrane depolarization, dysregulation 
of intracellular calcium homeostasis, calpain activation, and the release of 
pro-apoptotic proteins from mitochondria 
28-30
. The neurotoxic mechanism and 
the reason for the selective vulnerability of the striatum are not yet well 
understood. 
Superoxide dismutase (SOD) functions to protect cells from the effects of 
superoxide radicals by eliminating reactive oxygen species (ROS). Several 
reports have shown that SOD overexpression reduced the size of striatal lesions 
after 3-NP injection 
31
. Increased cytosolic Cu/ZnSOD is a compensatory 
response to the generation of ROS to reduce the toxic effects of the superoxide 
anion. In addition, the cumulative effects of ROS exposure cause the activation 
of various harmful cellular pathways 
32-34
. 
Apoptosis signal-regulating kinase-1 (ASK1), an early signaling element 
in the cell death pathway 
35
, is activated by ROS 
36
 and is required for 
ROS-induced apoptosis 
37
. Previous studies have indicated that increased 
activated ASK1impacts the presentation of neurodegenerative diseases 
10,12
.The 
rationale for targeting ASK1 was based on findings that oxidative stress is 
causally related to apoptotic neuronal cell death in neurodegenerative lesions 
commonly associated with abnormal protein fragments and aggregates 
34,38
. 
Although many investigations have shown that ASK1 is essentially involved in 
neuronal cell death triggered by various external injuries and expanded 
polyglutamine, the relationship of ASK1 and ROS in the selective striatal cell 
26 
 
death by 3-NP chronic and systemic infusion in mice remains is to be elucidated. 
In addition, ASK1 was suggested to play a role in mediating the cell death 
signal in striatal cells of aged mice that received 3-NP injections directly into 
the striatum.   
Here, we examined whether increased levels of ASK1 are reciprocal to 
the amount of ROS and also investigated the relationship between ASK1 
expression and striatal degeneration in 3-NP systemic infusion mice. We 
suggest that overexpressed ASK1 amplifies ROS damage, which can lead to 
cell death, and is a deleterious primary responder to oxidative stress in the 
striatum of 3-NP systemically infused mice. 
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II. MATERIALS AND METHODS 
 
1. Animal model  
Male SOD1-tg mice (C57BL/6-TgN; Jackson Laboratory, USA) and wild 
type (wt) male littermates were used in this study. All procedures were 
performed in accordance with the guidelines for the care and use of laboratory 
animals (Yonsei University), which have been approved by the Association for 
Assessment and Accreditation of Laboratory Animal Care (AAALAC). The 
animals were anesthetized with 2.0% isoflurane under 30% oxygen and 70% 
nitrous oxide using a vaporizer (VMC Anesthesia Machine, MDS Matrix, USA). 
The rectal temperatures were maintained at 37 ± 0.5°C. For the sustained 
chronic administration of 3-NP infusion, 3-NP (Sigma, USA) was dissolved in 
saline at a concentration of 0.5 mg per µl (pH 7.4). The prepared 3-NP solution 
or vehicle control was delivered by sustained infusion (180~220 mg/Kg/day) 
using osmotic mini-pump at an infusion rate of 0.5 µl/h for 7 days (Alzet, 
USA).  
 
2. ASK1gene silencing with siRNA and Administration of ASK1-peptide 
The ASK1 gene was silenced using siRNA against ASK1 (sense, 
GCUCGUAAUUUAUACACUGtt; antisense, 
CAGUGUAUAAAUUACGAGCtt; concentration 5µM; Ambion, Austin, TX, 
USA). After confirmation of efficiency in vitro, the transfecting reagent 
SiPORTNeoFX (Ambion, USA) and ASK1-siRNA or nonfunctional 
mutantRNA (control siRNA; 5'-AAG AGA AAA AGC GAA GAG CCA-3'; 
Ambion) were combined, mixed gently, and allowed to form siRNA liposomes 
for an additional 10 min at room temperature. An alzet micro-osmotic pump 
(Durect, USA) containing 100 µl of the transfection reagent or ASK1-siRNA 
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was then placed subcutaneously on the backs of the animals, and a brain 
infusion cannula connected to the pump was positioned in the striatum (A, 0.7 
mm; L, 1.2 mm, and D, 3.3 mm) for 7 days during 3-NP infusion. The mice 
were sacrificed 7 days after surgery, and the brains were processed for 
experiments. 
To restore ASK1, we synthesized an ASK1 peptide containing active sites 
(Thr845) from amino acids 836 to 875. The ASK1 protein was transported with 
the dried BioPORTER Quiktease (Sigma Aldrich) reagent to the striatum of 
SOD tg mice concomitant with 3-NP infusion for 7 days by a micro-osmotic 
pump containing 100 µl of ASK1 protein (0.1 mg/ml in saline). As a control, 
control-peptides were infused in the 3-NP-infused SOD-tg mouse striatum. To 
confirm the delivery, western blot analysis was performed with antibodies 
recognizing the Thr845 region. 
 
3. Immunohistochemistry  
To determine thepatterns of DARPP32 (Epitomics, USA) and ASK1 
(SantaCruz Biotechnology, Cell signaling) expression, we performed 
immunofluorescent staining. After sacrificing the animals, brains were removed, 
fixed, and cut into 20µm thickness coronal sections on a cryostat. The fixed sect
ions were incubated with a blocking solution, as described previously 
39
, a
nd incubated with the appropriate primary antibodies. After washing, the 
sections were incubated with fluorescein isothiocyanate (FITC)-conjugated 
secondary antibodies (Jackson ImmunoResearch, USA). For counter-staining, 
the sections were incubated with propidium iodide (PI, Sigma). After washing, 
stained tissue samples were mounted using Vectashield mounting medium 
(Vector Lab, USA) and coverslipped. The sectionswere then observed under 
a LSM510 confocal laser scanning microscope (Carl Zeiss, USA). 
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4. Western blot analysis 
The protein expression levels were analyzed by western blotting. Tissues 
were lysed in lysis buffer (20 mM Hepes–KOH, pH 7.5, 250 mM sucrose, 10 
mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 0.5mM PMSF, 
0.1mMsodium vanadate, 0.1mM proteinase inhibitor cocktail), the samples 
were homogenized with a Teflon homogenizer (Wheaton, USA), and then 
centrifuged at 8,000 g for 20 min. The lysates were loaded onto 
SDS-polyacrylamide gels and after migration, the proteins were 
electro-transferred onto a polyvinylidenedifluoride membrane (PVDF) 
(Millipore, USA), which was then blocked in 5% skim milk and incubated with 
one of the following primary antibodies: Cu/ZnSOD, MnSOD, ASK1, pASK1. 
After washing, the blots were incubated with horseradish peroxidase-conjugated 
secondary antibodies (Roche Diagnostics), and the bands were visualized with 
an enhanced chemiluminescence reagent (Amersham Biosciences).  
 
5. Apoptotic cell-death assay 
Apoptosis-related DNA fragmentation assays were quantified using a 
commercial enzyme immunoassay kit (Chemicon) and cytoplasmic 
histone-associated DNA fragment kit (Roche Diagnostics). According to the 
manufacturers’ protocols, cytosolic samples were used in each assay. In addition, 
we performed a TUNEL assay to detect cell death following the manufacturer’s 
protocol (Roche Diagnostics). Tissue were prepared as described above, and 
immune-fluorescent labeling was performed as previously described 
40,41
. The 
sections 
sections were counterstained with Hoechst (Molecular Probe, USA), mounted, 
and observed under a confocal laser scanning microscope (Carl Zeiss). The 
number of TUNEL-positive cells was counted in the striatum in three sections 
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from each mouse at different levels. 
 
6. ROS detection by staining 
ROS were investigated in the brains of 3-NP-infused mice using 
green-fluorescence (CM-H2DCFDA) in situ detection (Molecular Probes). Each 
mouse was placed in a stereotaxic frame (Stoelting) under general anesthesia, 
the CM-H2DCFDA (2 ul, 50ug/50ul dimethylsulfoxide) was infused for 10min 
into the striatum with a Hamilton syringe. The animals were sacrificed and 
trans-cardially perfused with heparin and formaldehyde 1h after infusion of 
CM-H2DCFDA. After preparing a frozen block of brain tissue, ROS was 
detected to appear as green dots by CM-H2DCFDA when examined under 
confocal laser scanning microscope (Carl Zeiss).The nucleus was stained with 
PI (Sigma). 
 
7. ROS detection by flow cytometry analysis  
CMXRosamine (MitoTracker-Red™) and CMH2-DCFDA (Molecular 
Probe) were obtained from Molecular Probes, dissolved in DMSO, and stored at 
20°C in the dark. Both MitoTracker (50 M) and CM-H2DCFDA (50 M) were 
administered into the cortex and striatum at the position described above 30 min 
before sacrifice. As a control, DMSO was injected in the same locations at the 
same time before sacrifice in some mice. Following this procedure, the mouse 
brain was removed, dissected out striatum, and minced finely with a scalpel. 
Minced striatum tissue was placed in separate tubes containing 2 ml digestion 
solution, and cells were dissociated with Accumax (Millipore) for 1 h at 37°C 
with agitation in the dark. The cell suspension was filtered through a 100-µm 
mesh (BD Biosciences) and diluted with PBS after fixing the single cells with 
3.7% formaldehyde in the dark, the fluorescence of the bound dyes within each 
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cell was analyzed using a FACSCalibur (BD Biosciences; over 100,000 total 
events; 5,000 events / gate), and the data were analyzed using Cell Quest 
software (version 3.3; BD Biosciences). Negative controls were prepared by 
reacting the tissues with PBS, FITC-conjugated IgG, or PE-conjugated IgG (BD 
Biosciences). 
 
8. Detection of DNA oxidation in mouse striatum 
We evaluated DNA oxidation usinga monoclonal antibody against 
8-OHdG according to a previous report 
32
. The brain tissue was fixed, and 
treated with DNase-free RNase (Roche) at 37°C for 1 h. Next, the sections were 
denatured in 4N HCl and neutralized with 50 mM Tris-base. After washing, the 
samples were incubated with an anti-mouse 8-OHdG antibody and also 
incubated with secondary antibody (MOM kit, Vector Laboratory, USA). The 
slides were mounted with Vectashield and coverslipped.  
 
9. Rotarod test 
The motor function of the animals was assessed with a rotarod apparatus 
(UgoBasile, USA), where the time that the animals were able to remain on the 
rod was measured at an accelerating speed from 4 to 40 rpm. Each mouse was 
pre-trained before implanting the osmotic pump filled with 3-NP or saline. 
After 30min rest period, and mice were then placed back on the rotarod for five 
trials of a maximum of 5 min at an accelerating speed.  
 
10. Statistical analysis 
Data are expressed as the mean ± SD. The statistical comparisons among 
multiple groups were performed using analysis of variance followed by Fisher's 
post hocprotected least-significant difference test, and comparisons between 
32 
 
two groups were performed using the unpaired t test (StatView, version 5.01; 
SAS Institute Inc., Cary, NC, USA).
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III. RESULTS 
 
1. Systemic infusion of 3-NP led to the formation of selective striatal lesions in 
wt, but SOD-tg mice 
Mice infused with 3-NP were examined for symptoms, and the 
degenerated brain region was validated with cresyl violet staining. Primarily, we 
confirmed an obvious decrease in body weight by 7 days after systemic3-NP 
reservoir implantation. The mouse body weight reduced an average of 70% of 
the initial body weight. Seven days after 3-NP administration, most mice 
presented with severe motor dysfunction in addition to weight loss. Histological 
evaluation of the 3-NP-infused mice at day 7 demonstrated striatal 
abnormalities and cell loss (Figure 1A). 
DARPP32 (dopamine- and cyclic adenosine monophosphate-regulated 
phosphoprotein), an established of striatal neuron marker, showed weak 
immunoreactivity in 3-NP-infused wt mice; however, the immunoreactivity in 
SOD- tg mice was significantly more dense (Figure 1B). The induction of DNA 
damage in striatal neurons was evaluated by terminal TUNEL staining (Figure 
2). The average number of TUNEL-positive nuclei was determined using 
multiple images in the four different mice of each group. Figure 2 reveals a 
statistically significant increase in TUNEL-positive nuclei in the 3-NP-infused 
wt mice, which was scarcely demonstrated by the DARPP32-positive cells.  
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Figure 1. Pathological examination in the striatum after systemic infusion 
of 3-NP. (A) Histological analysis was performed by cresyl violet staining (left). 
Body weight which measured on day 7 after infusion of 3-NP is expressed as a 
percentage of the weight before 3-NP infusion (right upper). Motor function is 
shown the duration sustained on the rotarod (right lower). (B) 
DARPP32-postive cells shown by immunohistochemistry was sparsely detected 
in the wt mice, while positive cells were more plentiful in the SOD-tg. 
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Figure 2. Apoptotic cell death in wt and SOD-tg mice. TUNEL-positive cells 
were more densely detected in the 3-NP-infused wt mice compared to the 
SOD-tg mice (left). A quantification graph is presented showing relative values 
of positive cells to counterstained cells in the unit area (right). *p<0.05. 
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2. Greater ROS production, oxidative damage and ASK1 levels and activity 
were detected in striatal lesions 
Using FACS analysis to quantify ROS, the total amount of ROS in the 
striatum significantly decreased from 9.57% in wt to 28.75% of SOD-tg mice 
(Figure 3). In contrast, there was a slight difference in the ROS quantity in 
mitochondria that were directly injured after 3-NP infusion between wt and 
SOD-tg mice (Figure 3), as revealed by FACS (wt, 99.99%; SOD-tg, 81.37%). 
As an alternative way to compare the changes in the amount of ROS, 
levels of MnSOD, and Cu/ZnSOD proteins, were determined by western blot 
analysis in the lesioned striatum from each brain. MnSOD protein amounts 
were not different in the damaged striatum between wt and SOD-tg, whereas 
relatively higher levels of Cu/ZnSOD were detected in SOD-tg than wt (Figure 
4). Unaltered pattern of MnSOD likely dues the direct attack of the 
mitochondrial dysfunction reagent, 3-NP. Cytosolic SOD levels, however, were 
greater in the SOD-tg than in the wt mice because of the restoring effect of SOD 
overexpression in the SOD tg mice. 
Representing DNA oxidation, 8-OHdG-positive cells were scarcely 
detected in the 3-NP-infused SOD-tg striatum; however, the immune-reactivity 
was strong in striatum of wt mice (Figure 5), suggesting that the ROS was 
produced following mitochondrial dysfunction and subsequent DNA damage 
(Figure 6). Under oxidative conditions, increased ASK1 protein levels, one of 
the first ROS-responsive molecules, were measured, and also measured 
increased pASK1 activated by phosphorylation at Thr845. The 3-NP infusion 
elevated total ASK1 protein amounts the SOD-tg and wt mice however, this 
increase was meager in the SOD-tg group. Corresponding to total ASK1 
amounts, the levels of pASK1 were also significantly lower in SOD-tg mice 
(Figure 2D). 
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Figure 3. Environmental changes and ROS level changes in the striatum 
after 3-NP infusion. After 3-NP infusion, CM-H2DCFDA-for evaluating total 
ROS levels, and MitoTracker-Red for mitochondrial ROS levels were assayed 
by flow cytometry (left), and the events are presented in a quantified graph 
(right). 
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Figure 4. The alteration of ROS scavenging enzyme protein level in the 
striatum of wt and SOD tg mice after 3-NP infusion. The MnSOD and 
Cu/ZnSOD protein levels in the striatum are shown in western blot analysis 
(left) and the quantitative values are presented in the graphs (right). 
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Figure 5. Oxidative DNA damage in the striatum of wt and SOD tg mice 
after 3-NP infusion. The 8-OHdG illustrates that the 8-OHdG-positive cells 
were more densely detected in the wt mice compared to the SOD-tg mice. A 
quantified graph is presented showing relative values of positive cells to 
counterstained cells in the unit area. 
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Figure 6. The changes of ASK1 protein and activity. The changes of ASK1 
and pASK1expression levels were assayed by western blot (left) and presented 
the quantified graph (right). *p<0.05. 
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3. ASK1 amounts mediated the striatal cell death without change of ROS level 
ASK1 gene silencing by siRNA sufficiently regulated ASK1 protein 
down (Figure 7). However, ASK1 silencing did not alter the amounts of ROS 
by 3-NP infusion. Indeed, ROS levels were similar or abundant both in the 
si-ASK1-treated and the si-control-treated wt mice. ROS detected with 
CM-H2DCFDA were scant in 3-NP-infused SOD-tg mice, while the 
CM-H2DCFDA in normal and ASK1-silenced 3NP infusion mice abundantly 
stained the striatal region with a punctuate shape (Figure 7). The results showed 
that the down-regulation of ASK1 did not affect ROS generation. Although the 
down-regulation of ASK1 did not affect ROS scavenging, it was sufficient to 
reduce cell death and improve the motor function (Figure 9). On the other hand, 
ASK1-peptide administration triggered cell death without increasing ROS 
levels.  
To confirm whether overexpression of ASK1 plays a role in mediating 
cell death, synthesized ASK-peptide was infused for 7 days in the SOD-tg mice 
striatum starting with 3-NP systemic infusion (Figure 8). In 3-NP-infused 
SOD-tg mice, the ROS levels were assessed in the control-peptide and 
ASK1-peptide treated groups by FACS (Figure 8). ASK1-peptide did not alter 
the amount of ROS generated. A DNA fragmentation assay showed that striatal 
apoptotic cell death occurred in the 3-NP-infused wt mice and decreased 
significantly in both SOD-tg mice and siASK1-treated wt mice with 3-NP 
infusion. In contrast, the DNA fragmentation recurred in the 
ASK1-peptide-treated SOD tg mice and also aggravate movement ability 
(Figure 9).  
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Figure 7. Down regulation and induction of ASK1. In the striatum, ASK1 
proteins were declined by siRNA-ASK1 (left), and quantified graph (right). 
CM-H2DCFDA in the striatum was detected in abundance in the si-control- or 
si-ASK1-treated wt mice, but was decreased in the 3-NP-infused SOD-tg mice. 
H2DCFDA, green; PI, red. 
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Figure 8. The effect of ASK1-peptide on ROS production level. Western blot 
analysis shows the expression levels of ASK1 in the striatum of wt or 
ASK1-peptide-added SOD-tg mice with 3-NP infusion. After 3-NP infusion, 
total ROS levels was evaluated with CM-H2DCFDA in each group (con-pep vs 
ASK1-pep) by flow cytometry. 
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Figure 9. The role of ASK1 in cell death and behavioral impairment. 
Apoptotic cell death using DNA fragmentation assay was found in each treated 
mouse striatum. Motor function is shown as the duration sustained on the 
rotarod in each treated group. *p<0.05. 
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IV. DISCUSSION 
 
The results of the present work show an improvement in behavioral 
impairment by ASK1 down-regulation, despite 3-NP infusion. We propose the 
hypothesis that ASK1 overexpression by systemic infusion of 3-NP promotes 
the formation of selective striatal lesions, and this occurs apart from ROS 
generation. The results of our study showed that increased 
ASK1andpASK1expression by harmful ROS signals augmented neuronal cell 
death in the striatum. 
Mitochondria are key players in the production of ROS and have been 
reported to have an important role in 3-NP injury-induced pathology 
42
. We 
evaluated amounts of total ROS produced in mitochondria and cytosol 
MitoTracker-Red CMH2XRos (MT Red CM-H2XRos) is a molecule that has 
been used to measure mitochondrial free radicals (MFRs) in various cell 
cultures. Because this dye has been reported to be sequestered into the nucleus 
and vesicles 
43,44
, we administered it to detect the generation of MFRs in 
3-NP-infused mice and to measure MFR generation in situ. Besides of 
mitochondrial dysfunction, 3-NP also raises cellular oxidative stress. The 
alteration of Cu/Zn-SOD is a compensatory mechanism that protects cells from 
free radical-induced damage, and systemic infusion of 3-NP altered Cu/Zn-SOD 
enzyme levels in this study. It has been previously reported that 3-NP induced 
major changes in SOD activity in the striatum of 3-NP-injected rats 
45
. Our 
study displayed that 3-NP caused a reduction in Cu/Zn-SOD, but had no effect 
on MnSOD protein levels. It can be inferred that the overexpression of 
Cu/ZnSOD is primarily responsible for cellular anti-oxidant protection in 
3-NP-infused SOD-tg mice, possibly by compensating for the overexpression of 
ROS. In wt mice, however, the endogenous antioxidant system could not 
enough to eliminate the increased ROS, as Cu/ZnSOD amounts were 
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diminished. The lesions of 3-NP indicate that striatal oxidative damage has 
occurred, and that this damage is associated with changes in the cellular 
antioxidant system 
46
. The Cu/ZnSOD levels were much greater in the SOD-tg 
mice compared to the wt mice, likely to overcome the oxidative damage. 
However, the changes in SOD protein levels during oxidative stress do not 
determine whether protect or not, although it is certain that overexpressed SOD 
amounts protect against harmful oxidative environments 
33
. 
Oxidative DNA damage results from direct ROS attacks. There are some 
types of oxidative DNA damage detective method. Among them, 8-OHdG 
results in oxidative DNA damage. The results presented here show that the 
oxidative DNA lesions are markedly augmented in the 3-NP-infused wt mouse 
brain. 
Once ROS are generated, they can damage mitochondria causing 
additional free-radical generation and loss of antioxidant capacity, leading to a 
deleterious cycle 
4
. Therapeutic prevention of oxidative stress has been 
proposed to “break the cycle” of cell death 4, and studies have been carried out 
in the neurodegenerative field attempting to modulate key enzymatic 
components that regulate oxidative stress 
33
. Our study was performed on the 
assumption that mitochondrial complex II inhibitors generate ROS, and 
contribute to cell death. Furthermore, because ASK1is known to be involved in 
ROS-induced cell death, we propose that ASK1plays an instrumental role and 
even amplifies this process. The ASK1 signaling-mediated cell fate decision 
appears to depend in part on the extent and duration of ASK1 amounts and its 
activation. A previous report found that a mutated SOD induced ER stress and 
activated the ASK1-mediated cell death pathway 
13
. Also, the deletion of ASK1 
mitigated neuronal loss and extended the life span of SOD1-mutated mice 
13
.  
Recent studies with animal models have revealed that oxidative stress is a 
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causative factor in the initiation and progression of Alzheimer’s disease (AD) 
and Parkinson’s disease, where antioxidants have the capacity to attenuate the 
phenotypes associated with these neurodegenerative disorders. Although 
antioxidants can prevent the oxidative stress-mediated progression of 
neurodegenerative diseases 
47
, antioxidant treatment is not sufficient to halt 
disease progression. We implied that inhibition of ASK1, the major downstream 
activator, may disrupt the positive feedback Therefore we propose that 
mitochondrial dysfunction by 3-NP induces an increase in ROS level; 
ROS-activated ASK1 mediates harmful oxidative signals; and cells eventually 
undergo apoptosis. The precise mechanisms have not yet been elucidated and 
have to be investigated. 
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V. CONCLUSION 
 
This study is summarized as followings: (1) systemic infusion of 3-NP 
increased ROS and led striatal cell loss; (2) ASK1 down-regulation decreased 
striatal cell death without scavenging ROS; (3) adding ASK1protein to SOD tg 
aggravated striatal degeneration; and (4) ASK1 activation induced by ROS is an 
important step of the 3-NP pathophysiology. Conclusively, this study indicates 
that ROS-induced ASK1 is an important step in the pathogenesis of 
3-NP-mediated striatal lesion, and suggests that ASK1 acts as an amplifier of 
the ROS signal cascade. Taken together, we suggest a combination of ASK1 
inhibition and ROS elimination for more effective therapy. 
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PART III 
 
 
 
 
Apoptosis signal-regulating kinase 1 mediates 3-nitropropionic acid 
toxicity and regulates C1q level via astrocyte TGF-beta 
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I. INTRODUCTION 
 
The systemic administration of 3-nitropropionic acid (3-NP) facilitates 
the development of selected striatal lesions and it remains unclear whether 
specific neurons are selectively targeted in 3-NP infused striatal degeneration. It 
is well known that 3-NP inhibits succinate dehydrogenase (SDH), mitochondrial 
complex II, to the same extent in both the cerebrum and the striatum 
4,25
, 
suggesting that 3-NP neurotoxicity occurs to the same extent in the cerebrum 
and the striatum. Although not entirely elucidated, the mechanisms of 
neurotoxicity induced by 3-NP have been shown to include the exhaustion of 
adenosine triphosphate, mitochondrial membrane depolarization, dysregulation 
of intracellular calcium homeostasis, calpain activation, and the release of 
pro-apoptotic proteins from mitochondria 
28,30,48
. The neurotoxic mechanism and 
the reason for the selective vulnerability of the striatum are not yet well 
understood. 3-NP has been used a pharmacologic model to study mitochondrial 
dysfunction in relation to Huntington’s disease (HD). However, speculation of 
selective regional neurotoxicity induced by 3-NP in different areas may not be 
accurate, and the molecular mechanisms underlining 3-NP-induced striatal 
lesion remain to be fully defined 
49
. 
Mitochondrial dysfunction can bring energy metabolism defects, 
oxidative stress, and defects in mitochondrial calcium usage. A number of 
studies have examined whether alterations in mitochondrial respiration 
contribute to the observed bioenergetic defects. Biochemical studies of brain 
and peripheral tissues from HD patients, as well as studies on HD cells and 
animal models, revealed decreased activity of several enzymes involved in 
oxidative phosphorylation such as complex I, II, III, and IV 
23,27,50-52
. 
Mitochondria are both a target and an important source of reactive oxygen 
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species (ROS). Although data on post mortem tissues show contrasting results 
on the presence of oxidative stress products 
53
, further analyses in animal 
models of HD, and systemic injection of 3-NP suggest that oxidative stress may 
play an important role in the pathogenesis of HD 
54
. It was found that pathways 
by which cellular energy is lost are clearly different in 3-NP-treated neural cells 
versus the same cells bearing the expanded polyglutamine tract of the HD 
protein, suggesting that mitochondrial defects may be a consequence of 
neurodegeneration 
55
. To relate with mitochondrial morphology, 3-NP did not 
induce translocation of the dynamin-related protein 1 (Drp1) to the 
mitochondria, and the Drp1 inhibitor Mdivi-1 did not affect the observed 
changes in mitochondrial morphology 
56
. Also, scavengers of ROS failed to 
prevent mitochondrial alterations. It shows a direct correlation that formation of 
mitochondrial permeability transition pores and autophagy induced by 3-NP 
treatment. Activation of autophagy preceded the apoptotic process and was 
mediated, at least partly, by formation of ROS and mitochondrial permeability 
transition pores. Superoxide dismutase (SOD) has function to protect cells from 
the effects of superoxide radicals by eliminating ROS. Several reports have 
shown that SOD overexpression reduced the size of striatal lesions after 3-NP 
injection 
31
.  
Apoptosis signal-regulating kinase-1 (ASK1), an early signaling element 
in the cell death pathway 
35
, is activated by ROS 
36
 and is required for 
ROS-induced apoptosis 
37
. Previous studies have indicated that increased 
activated ASK1impacts the presentation of neurodegenerative diseases 
12
. The 
rationale for targeting ASK1 was based on findings that oxidative stress is 
causally related to apoptotic neuronal cell death in neurodegenerative lesions 
commonly associated with abnormal protein fragments and aggregates 
34,38
. 
Although many investigations have shown that ASK1 is essentially involved in 
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neuronal cell death triggered by various external injuries and expanded 
polyglutamine, the relationship of ASK1 and ROS in the selectively striatal cell 
death by 3-NP chronic and systemic infusion in mice remains is to be elucidated. 
In addition of cell death initiation resulted from increased ASK1, depletion of 
neurotropic factor BDNF is major cause of striatal degeneration. Mitochondrial 
dysfunction alone is insufficient to elicit the striatal gene expression phenotype 
of HD, which the current report suggests the putative pathway generate striatal 
degeneration. Many experimental results derived from both clinical as well as 
basic research suggest a close correlation between BDNF deficiency and HD 
pathogenesis 
49
. In metabolic compromise, neurodegeneration caused by 3-NP 
involves three interacting processes. The main causes are energy impairment, 
excitotoxicity, and oxidative stress, which are related to HD pathogenesis 
49
. As 
report that examined the striatal gene expression in the both heterogygous and 
homozygous BDNF knock-out models is more like human HD than the other 
HD models, the results implicates that reduced trophic support as a major 
pathway contributing to striatal degeneration in HD 
57
.  
C1q is a component of the complement initiator C1 complex. During 
development, C1q is expressed in synaptic regions of developing postnatal CNS 
58
. Depending on the timing and local environment, the complement cascade 
can facilitate proper neuronal development or accelerate chronic inflammatory 
response contributing to neurodegeneration. Induced synthesis of C1q in the 
CNS has been seen in several injury models, such as viral infection 
59
, kainic 
acid treatment 
60
, stroke 
61
, and in hippocampal organotypic slice cultures 
stimulated with β-amyloid (Aβ) 62. In blood, C1q is normally present in 
complex with proenzymes C1r and C1s as the C1 macromolecular initiator of 
the classical complement pathway 
63
. The C1q response is biphasic. In stroke 
model, it was reported that increased C1q drove two independent 
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pathophysiological mechanisms involved in the processes of lesion formation 
and BBB disruption. (1) Excess C1q may lead to increased functional active C1, 
and resulted in increased activation of the classical pathway. (2) C1q is known 
to trigger a number of receptor-mediated cellular effects, even in the absence of 
downstream complement activation, and any of these might contribute to tissue 
injury 
64
. C1q plays a role as a pattern recognition receptor 
65
 that mediates the 
clearance of cells undergoing cell death by apoptosis 
66
, and can enhance 
the uptake of apoptotic cells 
67
. Exogenous plasma C1q, therefore, may play a 
role in the initiation of cell activation in microglial cells in the course of CNS 
diseases with blood-brain barrier impairment and may contribute in 
an autocrine or paracrine way to maintain and balance microglial activation in 
the diseased CNS tissue 
68
. Neuronal C1q expression is downregulated in the 
CNS in adulthood. Knock-out mice lacking C1q are characterized by large, 
sustained defects in CNS synapse elimination. Stevens et al proposed that 
complement-mediated synapse elimination may be aberrantly reactivated in 
neurodegenerative disease 
69
. 
Our previous results showing that striatal excitotoxic lesions differentially 
regulated molecules in each brain region suggest that changes in the levels of 
ASK1 including BDNF, could underlie the differential vulnerability of striatal 
neurons observed in 3-NP infusion or HD mice. The main goal of the present 
study is to characterize the regulation of BDNF in each subregion, cortex and 
striatum. The current study investigates that mild and chronic exposure of 
mitochondrial toxin can modulate the C1q level both in cortex and striatum via 
regulation of TGF-beta from astrocyte. Consequently we investigate how the 
BDNF is dominantly depleted in striatum, and finally whether striatal lesion is 
established in relating to ASK1 pathway.  
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II. MATERIALS AND METHODS 
 
1. Primary neuronal cell culture 
Primary cortical or striatal neurons were cultured with mouse pups and 
culture procedures are based on the widely used, non-feeder layer–based 
(without astroglial feeder cell layer). Embryonic day 14 pups were removed 
from the pregnant mother mouse. Cortex was dissected in Hank’s buffered salt 
solution (CMF-HBSS) and tissues were digested with 2.5% trypsin for 12 min 
in a 37°C water bath. The supernatant was removed, rinsed with three 
successive washes of HBSS and resuspended in neurobasal media (NB, Life 
Technologies) contained 0.2 mM GlutaMAX (Life Technologies) and 2.0% 
B-27 Supplement (Invitrogen). Cells were subsequently plated on 12 mm glass 
coverslips (Bellco) in 24 multi-well plates, pre-coated with 1 mg/mL 
poly-L-lysine (Sigma) at a density of 5x10
4
 cells per mL. Neurons were 
subsequently incubated at 37°C with 5% CO2 and remained in culture for 15 
days in vitro (DIV) to allow for the development and maturation of dendritic 
spines. Every 3–4 days, the neurons were fed by replacing one half of the fresh 
NB media. 
 
2. Animal model and lesion analysis 
In this study, male C57BL/6J mice were used and male SOD1-tg mice 
(C57BL/6-TgN; Jackson Laboratory, USA) were used in this study also. All 
procedures were performed in accordance
 
with guidelines for the care and
 
use of 
laboratory animals at Yonsei University, as approved by the Association for 
Assessment and Accreditation of Laboratory Animal Care (AAALAC). Mice 
were anesthetized with 2.0% isoflurane
 
under 30% oxygen and 70% nitrous 
oxide using a vaporizer (VMC Anesthesia Machine, MDS matrix; Orchard Park, 
NY, USA). Rectal temperature was controlled at 37 ± 0.5°C
 
with a 
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homeothermic blanket. For the sustained chronic administration of 3-NP mice 
model, 3-NP (Sigma, Milwaukee, WI, USA) was dissolved in saline to a 
concentration
 
of 0.5 mg per l (pH 7.4). The prepared solution of 3-NP was 
delivered by sustained infusion (180~190 mg/Kg/day) using osmotic 
minipumps at an infusion rate of 0.5 l/h for seven days (1007D; Alzet, 
Cupertino, CA, USA). Mice infused with 3-NP were examined the degenerated 
brain region was validated with cresyl violet staining, and magnetic resonance 
image (MRI) analysis. For MRI analysis, we performed MRI scans of mice on a 
horizontal bore (400 mm) 4.7 Teslar MR scanner (Brucker Biospin, Billerica, 
MA, USA) after mice were anesthetized with isoflorane. Images were obtained 
using a T2-weighted fast spin echo sequence. Diffusion images were also 
acquired. Temperature was maintained and respiration was monitored 
throughout the entire scan. Mice recovered quickly following the scan with a 
100% survival rate. 
 
3. Behavior and motor function test 
The motor functions of the mice were tested with the hindlimb clasping 
function. Mice were suspended by their tail and checked whether their hindlimb 
were clasped or not. The accelerating rotarod was performed on a rotarod 
apparatus (Ugo Basile North America Inc., Schwenksville, PA, USA) with 
speeds that varied from 4 to 40 r.p.m. for a maximum of 5  min. Each mouse 
was pre-trained prior to the implantation of the osmotic pump filled with 3-NP 
or saline. The training session was followed by a 30 min rest period, after which 
mice were placed back on the rotarod for five trials of five minutes maximum at 
accelerating speeds.  
 
4. PCR and realtime PCR 
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Total RNA was isolated from mice striatum and cortex. Isolated RNA was 
purified and its quality determined and quantified by spectrophotometric 
analysis at 260 nm and 280 nm (NonoDrop). Ribonucleic acid (1 g of total 
RNA) was reverse transcribed and cDNA was synthesized using PCR. The 
sequences of the forward and reverse BDNF primers are 5’-CGT GGG GAG 
CTG AGC GTG TGT-3’ and 5’-GCC CCT GCA GCC TTC CTT CGT-3’, 
respectively. A polymerase chain reaction (PCR) was performed as follows: 
initial denaturation at 95C for 10 min, amplification (30 cycles) for 30 sec at 
95C, 30 sec at 60C, 30 sec at 72C, and a final extension at 70C for 10 min. 
Following electrophoresis, RT-PCR products were visualized with a UV 
illuminator on an agarose gel. Reverse transcribed cDNA was also used in 
real-time PCR for ASK1 and p53. Real-time PCR was performed using a 
StepOne Plus (Applied Biosystems) or LightCycler rapid thermal cycler system 
(Roche Diagnostics, Lewes, UK). Reactions were performed in a 20 μl volume 
with 2 μl cDNA, 0.5 μM primers and reagents included in the DNA Master 
SYBR Green I mix (Roche Diagnostics). The forward (F) and reverse (R) 
primers used in the present study were shown in Table 1, which the primers for 
each target gene were designed by PrimerExpress 3.0 (Applied Biosystems). 
The reaction underwent pre-incubation step at 95℃ for 5 min, and was 
amplified by 45 cycles of denaturing at 95℃ for 15 sec and annealing and 
extending at 60℃ for 30sec. Detection of the fluorescent products was carried 
out at the end of the extension period. To assess an internal control GAPDH, 
house-keeping gene, mRNA was co-amplified in each sample. To confirm 
amplification specificity, the PCR was performed in no-transcript-control 
(NTC) and the PCR products from each primer pair were subjected to melting 
curve. For a melting curve analysis, the PCR products were melted by gradually 
increasing the temperature beginning at 65 °C in 0.2 °C steps. The 
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quantification data were analyzed with the ABI or LightCycler analysis 
software. Each sample was analyzed in triplicate to ensure the consistent results. 
Data analyzed by the comparative Ct method. The 2
−ΔΔCt
 equation was used to 
determine quantitative comparison of the amplification of the each gene (Table 
1). Each gene was analyzed in three biological replicates and three technical 
replicates. We used the average ΔCt from cortex or striatum. Data are presented 
as mean ± standard deviation (S.D.). Statistical evaluation of significant 
differences was performed using the Student’s t-test. Differences of p<0.05 
were considered statistically significant. 
 
5. ATP assay 
ATP level was evaluated by using ATP Colorimetric/Fluorometric Assay 
Kit (BioVision) and followed by manufacturer’s procedures. Primary neurons 
(1 x 10
6
 cells) or homogenized brain tissue (10 mg) were lysed ATP Assay 
Buffer. Each of samples was added to a 96-well plate and final volume was 
adjusted 50 ul with ATP Assay Buffer. For each well, reaction mix that is 
prepared with ATP assay buffer, ATP probe, and ATP converter was added 
50ul into each well containing ATP standard and samples. After mixing well, 
plate was incubated at room temperature for 30 min under protection from light 
(or dark room). In micro-plate reader, absorbance (OD 570 nm) was measured, 
and ATP level of each sample were calculated by applying the standard curve. 
 
6. Immunocytochemistry / immunohistochemistry and confocal microscopy 
To determine the pattern of localization of each molecule, we performed 
immunofluorescent staining. After sacrificing the mice, the brains were remov
ed, postfixed overnight in 3.7% formaldehyde, and stored in 30% sucrose. 
After fixation, the brains were cut into coronal sections of 20 m thickness on a 
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cryostat section and processed for immunohistochemistry. Fixed sections were 
incubated with blocking solution as described previously 
70
 and incubated 
with a primary antibody at a dilution of 1:100.
 
After washing, the sections 
were incubated with FITC-conjugated donkey anti-rabbit antibody (1:200; 
Jackson ImmunoResearch, West Grove, PA, USA). For counter-staining, the 
sections were incubated with DAPI or Hoechst 333342 (Molecular Probe). After 
washing, stained tissue samples were mounted using Vectashield mounting 
medium (Vector Lab, Burlingame, CA, USA). These sections
 
were then obser
ved under a confocal laser scanning microscope (Carl Zeiss, Thornwood, NY, 
USA). The sections were then cover-slipped and examined under a LSM510 
confocal laser scanning microscope (Carl Zeiss). 
 
7. Cell death assay 
Caspase-3 activity, apoptosis-related DNA fragmentation, and TUNEL 
assay were evaluated using a commercial enzyme immunoassay kit (Chemicon 
International, Temecula, CA, USA) and a cytoplasmic histone-associated DNA 
fragment kit (Roche Diagnostics), and in situ Cell Death detection kit (Roche 
Diagnostics) respectively. According to manufacturer instructions, cytosolic 
samples (20 g of protein) were used in each assay. Caspase-3 activity was 
determined to measure the quantity of bioluminescent substrate, DEVD-AFC, 
cleaved specifically by active caspase-3 as followed by manufacturer’s protocol 
(EMD Bioscience, Darmstadt, Germany). In addition, we performed a TUNEL 
assay to detect cell death following the manufacturer’s protocol (Roche 
Diagnostics). Tissue were prepared as described above, and immune-fluorescent 
labeling was performed as previously described
40,41
. The sections were 
incubated with 50 ul of the TUNEL reaction mixture, and the sections were 
counterstained with Hoechst 333342 (Molecular Probe, USA), mounted, and 
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observed under a confocal laser scanning microscope (Carl Zeiss). The number 
of TUNEL-positive cells was counted in the striatum in three sections from each 
mouse at different levels. 
 
8. ROS detection by in situ HEt and AP sites counting 
For in situ detection of oxidized Het (Molecular Probes, Eugene, OR, 
USA), HEt (stock solution 100 mg/ml in dimethyl sulfoxide), which is oxidized 
to ethidium by superoxide anion radicals, was administered intravenously 
through the jugular vein 1 h after KA or saline injection (200 μl, 1 mg/ml). The 
brain sections were incubated with Hoechst 33258 (2.5×10−3 mg/ml; Molecular 
Probes) and fluorescence was assessed microscopically at an excitation of 
510–550 nm and emission 580 nm for ethidium detection. The intensity and 
expression pattern of the oxidized HEt were observed using image analysis 
software (Metamorph ver4.6, Molecular Devices, Sunnyvale, CA, USA). To 
semiquantify ROS production, cells with oxidized HEt in the cytosol were 
counted and averaged in the entire field after random determination of four 
different areas, and the percentage of these cells to the total cells stained with 
Hoechst was calculated. 
To measure the oxidative DNA damage, apurinic/apyrimidic sites arisen 
by ROS were counted. The isolated genomic DNA was subjected to quantitative 
analysis of AP sites using a colorimetric assay, following the manufacturer’s 
protocol (Dojindo Molecular Technologies, Gaithersburg, MD, USA). Purified 
DNA was dissolved at a concentration of 100 μg/ml in TE and 10 μl of DNA 
solution was incubated with aldehyde reactive probe (ARP) solution. ARP in 
labeled DNA was measured using an ELISA-like assay in a microtiter plate. 
The number of AP sites per 10
5
 nucleotides was calculated based on the linear 
calibration curve generated for each experiment using ARP-DNA standard 
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solutions. 
 
9. Detection of DNA oxidation in mouse striatum 
We evaluated DNA oxidation usinga monoclonal antibody against 
8-OHdG according to a previous report 
32
. The brain tissue was fixed, and 
treated with DNase-free RNase (Roche) at 37°C for 1 h. Next, the sections were 
denatured in 4N HCl and neutralized with 50 mM Tris-base. After washing, the 
samples were incubated with an anti-mouse 8-OHdG antibody and also 
incubated with secondary antibody (MOM kit, Vector Laboratory, USA). The 
slides were mounted with Vectashield and coverslipped.  
 
10. RNA interference (gene silencing with siRNA) 
The ASK1 gene was silenced using siRNA against ASK1 (sense, 
GCUCGUAAUUUAUACACUGtt; antisense, 
CAGUGUAUAAAUUACGAGCtt; conc: 5 M; Ambion, Austin, TX, USA). 
The silencing efficiency was confirmed in PC12 culture cells. After 
confirmation in vitro, the transfecting reagent, SiPORT NeoFX (Ambion), and 
ASK1-siRNA or nonfunctional mutant
 
RNA (control siRNA, 5'-AAG AGA 
AAA AGC GAA GAG CCA-3'; Ambion) were combined, mixed gently, and 
allowed to form siRNA liposomes
 
for an additional 10 min at room temperature. 
A micro-osmotic pump (Alzet), containing 100 l of the transfection reagent 
only or ASK1-siRNA was then placed subcutaneously on the backs of the mice 
and a brain infusion cannula connected to a pump was positioned at the 
intra-striatum (anterior, 0.7 mm; lateral, 1.2 mm; depth, -3.3 mm) and also at 
the intra-cortex (anterior, 0.7 mm; lateral, -1.0 mm; depth, -2.0 mm). The 
designated solution was infused for seven days at a rate of 0.5 L/h during 3-NP 
infusion. The mice were killed seven days after surgery and their brains were 
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processed. . In case of primary neuron, siRNA was treated at 12 days in vitro 
(DIV) and incubated for 72 hours with media change and the neuronal cell were 
additional treated and collected at 15 DIV. 
 
11. Astrocyte conditioned medium 
To test the effect of astrocyte derived unknown factor on neuron, we used 
astrocyte (C8-D1A) which was purchased from American Type Culture 
Collection (ATCC, Manassas, VA, USA). Astrocytes were cultured in 
Dulbecco’s Modified Eagle’s Medium high glucose (DMEM, Invitrogen, 
Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS, 
Invitrogen, USA) and 1% penicillin-streptomycin solution (Thermo Scientific, 
Waltham, MA, USA).The cultures were maintained at 37°C in a humidified 
CO2 incubator. For obtaining astrocyte conditioned medium (ACM), confluent 
astrocyte cell cultures were washed and replaced with serum-free medium 
DMEM/F12 (Thermo Scientific, USA) without FBS (Invitrogen, USA). 
Astrocytes in serum-free media were treated with 1mM 3-NP and incubated 
another 4 hours and 24 hours each. After then, media were collected and 
removed cell debris by centrifuging at 1,000g × 10 min. To evaluate the effect 
of ACM on neurons, primary neurons were cultured in Neurobasal media (NB, 
Invitrogen, USA). At 15 DIV, neurons were replaced the neurobasal media with 
ACM exposed to 3-NP and incubated additionally 4 hours. Effects of ACM on 
neuron were assessed by neuronal dendrites changes and immunocytochemistry 
of PSD95.  
To further evaluate whether TGF-β1 of ACM mainly affected on neuronal 
dendrite degeneration and synaptic dysfunction, ACM was incubate with 
1μg/mL TGF-β1 antibody (Abcam, Cambridge, MA, USA) for 30 min at room 
temperature to deplete TGF-β1 from ACM by neutralizing the TGF-β1. ACM 
62 
 
neutralizing TGF-β1 was also treated on neuron for 4 hours and neuronal 
changes were observed with dendritic morphologies and immunocytochemistry 
of PSD95. According to the manufacturer’s information, TGF-β1 is neutralized 
50% of the bioactivity when 0.25μg/mL TGF-β1 antibody was treated in HT2 
cell line.  
 
12. ELISA 
The samples for ELISA were prepared in animal peripheral blood serum 
and ACM. Each ACM exposed to 3-NP for 4 hours and 24 hours each was 
collected and concentrated. Prepared ACM was performed according to the 
manufacturer's provided protocol. Standards were diluted with each assay buffer 
provided. Each assay was followed with each procedure. Plates were read and 
data were acquired. ELISA kits were obtained for total TGF-β1 (BioLegend, 
San Diego, CA, USA) and mouse C1q (Hycult Biotech, Uden, Netherlands). 
 
13. Statistical analysis 
Data are expressed as mean ± SD.
 
The significance of differences among 
multiple groups was evaluated by ANOVA followed by Fisher's post hoc 
protected least-significant
 
difference test, while two groups were compared 
using unpaired t tests (StatView, version 5.01; SAS Institute Inc, Cary, NC).
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III. RESULTS 
 
1. Selective striatal lesions were formed by systemic infusion of 3-NP in mice 
Histological evaluation of the 3-NP-infused mice
 
(n = 11 per time point) 
from day five demonstrated striatal abnormalities and scanty striatal lesions at 
day three (Figure 1A). We validated the lesion of mice infused by 3-NP using 
cresyl violet staining and the motor function test (Figure 1). Additionally 
DARPP32 (dopamine- and cyclic adenosine monophosphate-regulated 
phosphoprotein), an established of striatal neuron marker, showed weak 
immunoreactivity in 3-NP-infused mice (Figure 1). With motor function test, 
neurological and behavioral deficit were observed whether they showed 
hindlimb clasping, hindlimb dystonia and kyphotic posture, and whether they 
can adjust to a imbalanced postural challenges. Mice infused 3-NP were not 
displayed neurological deficit until day three (data not shown). In contrast, five 
days later, mice apparently showed hindlimb clasping (Figure 2) as well as 
hindlimb dystonia, kyphotic posture, and failure of imbalance adjustments (data 
not shown). Motor dysfunction was also evaluated at day three and seven 
following 3-NP infusion. Motor symptoms were prominent at day three
 
and had 
worsened by day seven. The majority of 3-NP animal models could not remain 
on the rotarod (Figure 2, n = 12 each). It was determined to getting body weight 
loss along with the days after systemic 3-NP administration. The body weight 
fell down to 70% of initial body. At 7 days after 3-NP administration, the most 
of mice were presented the obvious symptoms like as weight loss and severe 
motor dysfunction, and consequently striatal lesion was formed in the mice. 
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Figure 1. Chronic infusion of 3-NP induces selective striatal lesion. Cresyl 
violet staining demonstrates selective striatal cell loss at day seven.  
Corresponding to the result of cresyl violet staining, striatal neuron stained by 
DARPP32 were almost disappeared.  
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Figure 2. Chronic infusion of 3-NP induces behavioral and motor 
dysfunction.  At day seven, the mice got hindlimb impaired. On the rotarod, 
they could not perform the rotarod test besides were hard to move. *p<0.05. 
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2. Mitochondrial dysfunction was triggered and ROS level was raised by 3-NP 
infusion  
ATP measurements following infusion of 3-NP presented significant 
decreases in ATP content, according to 3-NP infused duration. At days three 
when the lesion was not detected, ATP level was sustained similar to the normal 
level (Figure 3A). However, for 7 days infused with 3-NP produced a 40% 
decrease in ATP levels (Figure 3A). The observed 40% reduction in ATP levels 
caused by application of 3-NP represents a significant decrement in neuronal 
metabolic capacity. Brain tissue and neurons exposed to 3-NP in this manner 
appeared morphologically normal, both initially and 3~4 days after the systemic 
exposure of insult. After 3–NP infusion, ROS production and oxidative DNA 
damage were detected by hydroethidine (HEt) oxidation, augmented AP sites 
number and the 8-hydroxy-2'-deoxyguanosine (8-OHdG)-positive cells by 
immunohistochemistry respectively. Oxidized Het by ROS are visible as small 
red particles. In contrast of red particles scantly shown in the normal tissue, a 
plenty of oxidized Het shown as red particles were displayed in the 3-NP 
infused tissue (Figure 3B). By infusion of 3-NP, oxidized HEt were increased 
and distributed in the striatum as well as cortex. Additionally 
apurinic/apyrimidic (AP) sites arisen by ROS were augmented from 3-NP 
infusion and the number of AP sites reached to summit at day seven (Figure 3C). 
Oxidative DNA damages triggered by 3-NP infusion were also examined with 
8-OHdG immunohistochemistry, and there were detected plenty of 
8-OHdG-positive cells both in the injured cortex and striatum corresponding to 
the result of HEt and AP sites number (Figure 3D). Representing DNA 
oxidation, 8-OHdG-positive cells were plenty in the 3-NP-infused striatum, and 
its immune-reactivity was strong in striatum. It suggests that the ROS was 
produced following mitochondrial dysfunction and subsequent DNA damage 
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Figure 3. Infusion of 3-NP increases mitochondrial dysfunction and DNA 
damage. (A) ATP level decreased at day 7. (B) Hydroethidine bound with ROS 
is shown in red dots. (C) AP sites derived by overproducing ROS increased by 
day-dependent manner. (D) Another oxidative damage marker, 
8-OHdG-positive cells also demonstrate oxidative damage by 3-NP infusion. 
*p<0.05. 
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3. Brain-damage and apoptotic cell death were induced in the lesion of 3-NP 
infusion 
The longer period of 3-NP infusion sustained, the greater amount of 
neuronal apoptotic cell death was occurred. The event impacted the cortex more 
than the striatum (Figure 4). The induction of DNA damage in striatal neurons 
was evaluated by terminal TUNEL staining (Figure 4). At day seven, the 
average number of TUNEL-positive nuclei was determined using multiple 
images in the four different mice of each group. These results demonstrate a 
statistically significant increase in TUNEL-positive nuclei in the 3-NP-infused 
mice, which was corresponded to the result of the DARPP32-positive cells in 
Figure 1. Caspase-3 and caspase-6 as the main effector of apoptotic cell death 
were evaluated the protein level with western blot analysis and also measured 
the activity with colorimetric analysis. It was demonstrated that caspase-6 was 
greatly higher in the striatum of 3-NP infused mice whereas caspase-3activity of 
3-NP mice striatum was not much higher than the difference in caspase-6same 
different activity even after 3-NP chronic administration (Figure 4). 
To evaluate the primary response protein amendment, both of ASK1 and 
p53 protein were analyzed by western blot assays (Figure 4 and 5); ASK1 was 
regarded as the initial responder to ROS, and p53 to DNA damage generated by 
3-NP infusion each. The results revealed that the amounts of ASK1 and p53 
protein were greater in 3-NP-infused mice than in vehicle-infused mice, and 
pASK1 (Thr845) was dominantly present at higher levels in the cortex than the 
striatum of 3-NP-infused mice (Figure 4). Levels of pASK1 (Thr845) were 
elevated in the cortex of 3-NP-infused mice, and the quantified graphs represent 
normalizing values with ASKl protein amounts. In the other hand, it is 
demonstrated in the striatal region that BDNF distribution and amounts were 
apparently reduced in the striatum at day seven after 3-NP infusion (Figure 7). 
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Figure 4. Apoptotic cell death was induced in the lesion of 3-NP infusion. At 
day seven, TUNEL-positive nuclei was detected mainly in the striatum 
especially lateral striatal region. Cell apoptotic cell death was assessed by cell 
death detection assay with cell lysates. Caspase-3 and caspase-6 were measured 
the activity with colorimetric analysis.  
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Figure 5. ASK1 protein level and activation were induced in the lesion of 
3-NP infusion. The amounts of ASK1 protein were greater in 3-NP-infused 
mice than in vehicle-infused mice, and pASK1 (Thr845) was at higher levels in 
the cortex than the striatum of 3-NP-infused mice. Levels of pASK1 (Thr845) 
were significantly elevated in the cortex of 3-NP-infused mice, and the 
quantified graphs represent normalizing values with ASKl protein amounts.  
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Figure 6. Protein level of p53 increased in the lesion of 3-NP infusion. DNA 
damage generated by 3-NP infusion triggered p53. The amounts of p53 protein 
were greater in 3-NP-infused mice than in vehicle-infused mice. 
Immunohisochemistry of p53 demonstrated in the striatal region that 
p53-postitive cells were more detected in the wt than SOD1 tg and distributed in 
nucleus at day seven after 3-NP infusion. 
Scale bar = 20 m; *p < 0.01 
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Figure 7. Infusion of 3-NP decreases BDNF expression. 
Immunohistochemisty showed that BDNF was almost depleted in striatum and 
cortex at day 7. Western blot analysis was also demonstrated the same results. 
*p<0.05. 
 
 
73 
 
4. Downregulation of ASK1 prevented 3-NP induced cell death, BDNF 
depletion, and subsequently improved the neurologic impairment 
Decreases in BDNF protein levels in the cortical and striatal regions were 
apparently inhibited in siRNA-ASK1 treated 3-NP mice as compared to 
siRNA-control treated 3-NP infusion mice (Figure 8, n = 6 each). In IHC and 
western blot analysis of BDNF, the BDNF-positive cells were barely detected in 
the 3-NP infused cortex and striatum of the siRNA-control, whereas 
BDNF-positive cells increased as a result of BDNF restoration, particularly in 
the striatum of siRNA-ASK1 treated mice (Figure 8). In ASK1 gene-silenced 
mice, protein levels of BDNF were significantly higher whereas BDNF 
transcript levels were also restored in the cortex (Figure 8, n = 6 each). This 
result suggests that the inhibition of ASK1 blocks depletion of BDNF protein in 
the cortex and supply of BDNF protein into the striatum. ASK1 silencing not 
only resulted in increased levels of BDNF protein, but also in the significant 
recovery of BDNF mRNA levels in 3-NP injured and ASK1 gene silenced 3-NP 
infusion mice. 
In vivo MRIs of siRNA-ASK1 treated 3-NP infusion mice were 
performed after the infusion of 3-NP and siRNA on day seven. In the 
contralateral side of the mice brain, progressive enlargement was evident in the 
lateral ventricles and atrophy was detected in the striatum. In the ipsilateral side, 
siRNA-ASK1 treated side, ventricular enlargement and striatal atrophy did not 
indicate severe regression (Figure 9, n = 4 each).  
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Figure 8. Down-regulating ASK1 prevents 3-NP induced BDNF depletion. 
BDNF amounts in cortex and striatum. Decreases of BDNF protein were 
prevented in ASK1-siRNA treated 3-NP mice compared to control-siRNA group. 
The immunohistochemistry of BDNF was also responsive to WB. The 
BDNF-positive cells were barely detected in control-siRNA group, whereas 
BDNF-positive cells were detected much more in ASK1-siRNA treated mice.  
Scale bar = 100 m; cor, cortex; str, striatum; *p < 0.01 
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Figure 9. Down-regulation of ASK1 reduced striatal lesion size by 3-NP. 
MR images are demonstrated that the lateral ventricles in the contralateral side 
were enlarged and striatal atrophy was progressed. In the ipsilateral side, 
ASK1-siRNA treated side, ventricular enlargement and striatal atrophy were not 
indicated.  
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5. Infusion of 3-NP leads to striatum-selective astrocyte reactivation and 
changes the distribution of secreted BDNF, TGF-β1, and C1q protein in the 
damaged subregions 
Neurons, stained with NeuN, homogeneously displayed in the cortex and 
striatum of control animals (Figure 10, left pannel), while neuronal staining was 
hardly found in the striatum of 3-NP infused mouse brain. Moreover, the 
neuronal loss was much more severe in striatum than in the cortex after 3-NP 
infusion for 7 days. Astrocytes were also weakly detected along the cortex and 
striatum of control rats (Figure 10, right pannel). In 3-NP infused mouse brain, 
GFAP immunostaining showed that astrocytes were strongly reactivated in the 
lateral striatum. However, distribution of reactivated astrocytes was not the 
whole striatum or cortex but lateral striatum where is the boundary between 
striatum and cortex. This result could be a hint that astrocyte related secreting 
molecule might be involved in selective striatal lesion formation followed by 
neuronal factors to impose neuronal loss or degeneration. Considering astrocyte 
derived molecules could involve in the neuronal loss, TGF-ß and C1q secretion 
level was assayed (Figure 11). The secretion levels of two molecules increased 
at day 3 when the lesion is not detected and also at day 7 when the lesion was 
definite. In addition, when the ASK1 is down-regulated, both of TGF-beta and 
C1q decreased their secretion level. After 3-NP infusion, TGF-β1 was highly 
secreted at 3 days when it is the time before lesion formation. At 7 days when 
the specific striatal lesion was fully and completely developed, TGF-β1 level 
was reduced rather than that at 3 days (Figure 11). C1q secretion level was also 
corresponding to the level of TGF-β1 (Figure 11).  
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Figure 10. Astrocytes were strongly reactivated by infusion of 3-NP. 
Astrocytes reactivated selectively in the lateral striatum. 
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Figure 11. TGF-beta and C1q secretion was triggered by 3-NP infusion. The 
secretion level of TGF-β1 and C1q evaluated by ELISA. The secretion levels of 
two molecules increased at day 3 when the lesion is not detected and also at day 
7 when the lesion was definite. In addition, when the ASK1 is down-regulated, 
both of TGF-β1 and C1q decreased their secretion level.  
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6. TGF-β1 is differentially expressed in the damaged brain subregions and 
astrocyte derived ASK 1 by 3-NP involves in TGF- β1 
TGF-β1 mRNA expression evaluated using RT-PCR was different in 
various brain regions of 3-NP-induced mice (Figure 12, upper). The alteration 
of TGF-β1 in the cortex and striatum were assessed in the brains of 3-NP 
infused mice (Figure 12, upper). Corresponding to the result of TGF-β1 ELISA 
in the whole blood serum, more TGF-β1 transcripts were present in the striatum 
than in the cortex of 3-NP-infused mice. It showed that TGF-β1 differentially 
expressed in brain subregions by days after 3-NP infusion. TGF-β1 transcript 
highly increased in striatum while cortical TGF-β1 transcript was not shown the 
significance. To test that the expression level of TGF-β1 is affected by ASK1 
level, we down-regulated the ASK1 level with siRNA-ASK1 into striatlal 
region. Down-regulating ASK1, however, did not lower TGF-β1 transcript in 
striatum either cortex. Nevertheless, down-regulating ASK1 showed 
neuroprotective effect in striatal neuron stained with NeuN (Figure 12, lower).  
To further evaluate the effect of TGF-β1 on neuron, we used astrocyte cells 
exposing to 1mM 3-NP for chronic and mild intoxication. Exposure of 3-NP 
onto astrocyte increased TGF-β1 expression level and ASK1 protein amounts 
(Figure 13). As same in the above results of animal, down-regulating ASK1 had 
no effect to reduce astrocyte TGF-β1 transcription level (Figure 13). 
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Figure 12. TGF-beta is differentially expressed in brain subregions and 
astrocyte derived ASK 1 by 3-NP involves in TGF- β1. (A) Realtime RT-PCR 
of TGF-β1 in cortex and striatum. TGF-β1 transcript highly increased in 
striatum while cortical TGF-β1 transcript was not shown the significance. 
Down-regulating ASK1 did not lower TGF-β1 transcript. (B) 
Immunohistochemistry of NeuN in each cortex and striatum. Although 
down-regulated ASK1 did not alter the transcriptional level of TGF-β1, 
down-regulating ASK1 showed neuroprotective effect in striatal neuron. 
 
A 
B 
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Figure 13. Infusion of 3-NP alters TGF- β1 and ASK1 in astrocyte. 
Astrocytes were cultured and exposed to 1mM 3-NP for chronic and mild 
intoxication. (A) The secreted TGF-β1 was augmented and (B) also ASK1 
protein level of astrocyte increased by 3-NP treatment. (C) Down-regulating 
ASK1 did not reduce astrocyte TGF-β1 transcript.  
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7. TGF-β1 secreted by astrocyte triggers neuronal C1q degenerating neuronal 
dendrites and ASK1 mediates the event 
To evaluate whether astrocyte conditioned media (ACM) containing 
TGF-β1 can affect neuron cytotoxicity, we used primary neuron culture. As 
same in the case of astrocyte culture, neuronal cells were exposed to 1mM 3-NP 
for chronic and mild intoxication. The ATP level is similar pattern to that of 
animal model (Figure 14A). Specifically for assessing the regulating role of 
astrocyte on neuron, ACM was prepared to expose to 3-NP for 4 hours and 
24hours each. Neuron was replaced by prepared ACM and then incubated for 
another 4 hours. The qPCR results demonstrated that neuronal C1q transcript 
was highly expressed under ACM (Figure 14B). When ASK1 and C1q were 
down-regulated in neuron, however, neuronal C1q transcript decreased even if 
under ACM containing TGF-β1. When neuronal media were replaced by ACM, 
although neuronal cell death was not detected, there were some changes in the 
neuronal dendrites by immunostaining with PSD95 (Figure 14C). Under 
condition of augmented astrocyte TGF-β1 in 3-NP infused animal, C1q 
secretion level increased as mentioned above that ASK1 expression level was 
linked with C1q and followed by change of ASK1 expression level (Figure 11) 
After 3-NP infusion, C1qR-positive cells were detected more in ASK1 
downregulated striatum (Figure 15). We assumed that changed C1q level could 
bring the striatal cell loss. To certify the assumption, we applied C1q directly 
into the striatum and cortex each and examined whether neuronal cell demise 
can be caused by C1q or not. As shown in Figure 15, lots of TUNEL-positive 
cells were in striatum contrast to cortex, even though the same dose of C1q 
(Figure 15). 
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Figure 14. Astrocyte conditioned media (ACM) affect on neuron to trigger 
neuronal C1q degenerating neuronal dendrites and ASK1 mediates the 
event. (A) The ATP level is lowered at 24 hours after exposure to 1mM 3-NP. 
(B) Astrocytes were exposed to 3NP for 4 hours and 24 hours each. Neuron was 
replaced by prepared ACM and then incubated for another 4 hours. Neuronal 
C1q transcript is highly expressed under ACM. When ASK1 and C1q were 
down-regulated in neuron, however, neuronal C1q transcript decreased even if 
under ACM. (C) When neuronal media were replaced by ACM, although 
neuronal cells were not died, there were some changes in the neuronal 
dendrites.  
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Figure 15. Infusion of 3-NP increases C1qR mediated by ASK1. (A) At five 
days after 3-NP infusion, C1qR-positive cells were detected more in ASK1 
downregulated striatum. According to increased C1q secretion level, 
C1qR-positive signals were detected in the striatal damaged lesion. 
Down-regulating ASK1 reduced the C1qR-postive signals despite of 3-NP 
infusion. (B) When C1q directly injected into the striatum and cortex each, lots 
of TUNEL-positive cells were in striatum contrast to cortex, even though the 
same dose of C1q. 
A 
B 
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IV. DISCUSSION 
 
The results of the present work show an improvement in behavioral 
impairment by ASK1 down-regulation, despite 3-NP infusion. We propose the 
hypothesis that (1) ASK1 overexpression by systemic infusion of 3-NP 
promotes the formation of selective striatal lesions, and this occurs apart from 
just ROS generation. (2) ASK1 may differentially regulate C1q secretion level 
via active TGF-beta in each brain subregion of cortex and striatum, 
consequently involved in axon degeneration of corticostriatal projection neuron. 
When brain is mildly and chronically exposed to mitochondrial toxin, 
presynaptic neuron (in cortical neuron) degrades first, and then postsynaptic 
neuron of striatal MSN neuron withers as a consequence of it. We suppose that 
striatal lesion formation results from the non-autonomous events as hypothesis 
described above. 
The systemic administration of 3-NP causes selective degeneration of 
neurons in the lateral striatum, few reports have infused 3-NP into mice using a 
subcutaneous osmotic pump, which differs from previous studies on rats 
4,28,71
. 
HD is caused by a dominant inherited expansion of CAG repeats in the 
Huntington gene. Thus, many aspects of HD cannot be mimicked by 3-NP. 
However, recent research shows that mitochondrial defects and oxidative stress 
may play a key role in HD pathogenesis, further supporting the potential utility 
of the 3-NP model of striatal degeneration 
72
. Our results demonstrated that the 
systemic infusion of 3-NP into mice caused selective striatal lesions, apparent 
motor dysfunction, and cell death by day seven (Figure 1). The 3-NP infusion 
mice model was used in this study because a treatment could be concomitantly 
added at the beginning of pathogenesis. By treating the siRNA-ASK1 with 
3-NP infusion, this provided a chance to examine selective striatal vulnerability 
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resulting from systemic 3-NP administration. chronic systemic administration of 
3-NP in rats and non-human primates produces homogeneous inhibition of 
complex II (SDH) within the brain and not solely the striatum 
28,73
, despite 
evident striatal degeneration associated with behavioural abnormalities that are 
reminiscent of HD 
27,74
. In our study we were mainly interested in studying mild 
3-NP neurotoxicity. We used 3-NP at a concentration that while decreasing SDH 
activity by approximately 75% did not affect the activity of the other 
mitochondrial complexes or ATP levels (Figure 3). Indeed, maintenance of 
cellular ATP levels is important for apoptotic cell death.  
Mitochondria are key players in the production of ROS and have been 
reported to have an important role in 3-NP injury-induced pathology 
42
 and also 
oxidative DNA damage results from direct ROS attacks. There are some types 
of oxidative DNA damage detective method. Among them, 8-OHdG results in 
oxidative DNA damage. The results presented here show that the oxidative 
DNA lesions are markedly augmented in the 3-NP-infused wt mouse brain. 
Once ROS are generated, they can damage mitochondria causing additional 
free-radical generation and loss of antioxidant capacity, leading to a deleterious 
cycle 
4. Therapeutic prevention of oxidative stress has been proposed to “break 
the cycle” of cell death4, and studies have been carried out in the 
neurodegenerative field attempting to modulate key enzymatic components that 
regulate oxidative stress 
33
. Our study was performed on the assumption that 
mitochondrial complex II inhibitors generate ROS, and contribute to cell death. 
Furthermore, because ASK1is known to be involved in ROS-induced cell death, 
we propose that ASK1 plays an instrumental role and even amplifies this 
process. The ASK1 signaling-mediated cell fate decision appears to depend in 
part on the extent and duration of ASK1 amounts and its activation. A previous 
report found that a mutated SOD induced ER stress and activated the 
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ASK1-mediated cell death pathway 
13
. Also, the deletion of ASK1 mitigated 
neuronal loss and extended the life span of SOD1-mutated mice 
13
. Recent 
studies with animal models have revealed that oxidative stress is a causative 
factor in the initiation and progression of Alzheimer’s disease (AD) and 
Parkinson’s disease, where antioxidants have the capacity to attenuate the 
phenotypes associated with these neurodegenerative disorders. Although 
antioxidants can prevent the oxidative stress-mediated progression of 
neurodegenerative diseases 
47
, antioxidant treatment is not sufficient to halt 
disease progression. We implied that inhibition of ASK1, the major downstream 
activator, may disrupt the positive feedback Therefore we propose that 
mitochondrial dysfunction by 3-NP induces an increase in ROS level; 
ROS-activated ASK1 mediates harmful oxidative signals; and cells eventually 
undergo apoptosis. The precise mechanisms have not yet been elucidated and 
have to be investigated.  
Because the majority of striatal BDNF is synthesized by cortical neurons, 
the data also imply that cortical dysfunction contributes to HD’s hallmark 
effects on the basal ganglia 
57
. Finally, the results suggest that striatal lesions 
caused by mitochondrial toxins may arise via pathways different from those that 
drive striatal neurodegeneration in 3-NP infused animal. According to the P35 
expression profiles, the similar mRNA expression changes argue that the MSNs 
in HD and BDNF-deprived environments suffer from similar insults 
57
. The 
3-NP profile appears substantially attributable to astrocytosis, a common 
component of HD, but not HD-specific or necessarily a significant feature of 
early HD 
75
. Through the study, reductions in striatum-enriched mRNAs 
associated with MSN dysfunction failed to appear although the 3-NP regimen 
has been optimized to produce striatal lesions. The result may indicate that 3-NP 
lesions arise via rapid apoptotic mechanisms 
57
. BDNF is primarily supplied to 
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the striatum via anterograde transport down corticostriatal axons 
76
, which 
BDNF depletion in the striatum may be particularly sensitive to disrupted 
axonal transport 
57
. In the current study, systemic 3-NP infusion was followed 
by BDNF protein decreased in cortical neurons (Figure 7). In case of HD, Colin 
et al. also reported that BDNF flow and release is increased via Htt 
phosphorylation 
76
. Collectively in the previous reports, we observed that the 
BDNF protein levels primarily and abundantly increased in the cortex and then 
BDNF proteins were also restored the injured striatum after the siRNA-ASK1 
treatment of 3-NP infused mice. Recent reports indicate that disturbance of 
BDNF transportation to the striatum results in striatal selectivity in 3-NP 
degeneration as opposed to toxicity of mHtt itself 
5,22
. Patients later exhibit 
dystonia, which indicates the development of striatal lesions. Brain MRIs 
confirm this also 
77
. These clinical findings strongly support an initial 
BDNF-transport disturbance induced by cerebral mHtt that may result in striatal 
vulnerability. Some reports elucidated the relationship between mHtt fragments 
and BDNF depletion as that endogenous intact Htt protein disappeared after 
3-NP treatment in cultured cells, resulting in reduced BDNF protein levels 
25,78
. 
Moreover, the restoration of depleted cortical BDNF facilitates successful HD 
treatment in the HD patients 
79
. Recovery of BDNF by gene silencing of ASK1 
led the striatal atrophy in the ipsilateral side infused siRNA to be ameliorated 
though MRI images, and eventually motor function to be improved (Figure 9). 
Our results imply that the selective elimination of ASK1 by siRNA as well as 
its activity inhibits caspase-6 activity and impedes striatal neurodegeneration in 
vivo. The gene silencing of ASK1 facilitates the restoration of cortical BDNF, 
which then increases the supply of BDNF protein in the striatum. BDNF is 
highly concentrated in the nervous system but is also found in the blood of 
human and other mammals, where its function is poorly understood 
80
. Although 
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it is still unclear how BDNF expression and metabolism in human peripheral 
tissues are regulated, changes in serum BDNF levels in rats during development 
correlate with those in the brain 
81
. Studies in rodents in which BDNF mRNA 
and protein have been evaluated both in basal conditions and after 
pharmacological treatment are promising 
82,83
. In particular, the level of BDNF 
mRNA can be monitored systematically, and it correlates with disease 
progression in R6/2 mice and HD rats 
84
. Blood BDNF mRNA is also sensitive 
to pharmacological treatments. It can be used to test compounds in HD mice, 
predict their ability to stimulate the production of BDNF in the brain, and 
possibly evaluate their therapeutic efficacy in the animals by a blood test. 
However, detection of BDNF in HD patients requires standardization in the 
collection and the processing methodology of a large number of samples 
C1q, a complement factor deposited in classical innate immune pathway, 
has been reported to affect ROS and mediate neuronal injury during AD 
85
. The 
study reported that the blocking of neuronal calreticulin by its antibody 
abrogated ROS by C1q, and suggested that the C1q may be an important factor 
contributing to neuronal oxidative stress and neuronal demise during AD 
85
. In 
that TGF-β signaling, Serine-threonine kinase receptor-associated protein 
(STRAP) which is identified an interacting partner of ASK1was issued to 
interact with TGF-β receptors and block TGF-β signaling 86. ASK1 
phosphorylated STRAP, inhibition of ASK1 suppress the hydroxyl peroxide 
induced apoptosis mediating STRAP by directly interacting between ASK1 and 
STRAP. The regulatory role of ASK1 in C1q level may be consistent with this 
report that the ASK1 is working as a negative regulator of STRAP activating 
TGF-β signaling. Until now, the signals controlling C1q expression and 
function remain elusive. Previous report identified that retinal TGF-β play a key 
regulator role in of neuronal C1q expression and synaptic pruning in the 
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developing visual system 
87
. C1q rapidly upregulated by TGF-β from astrocyte, 
and TGF-beta is essentially needed to that. Specific in retinal development and 
eye-segregation, controlling of C1q level by TGF-β is decisive 88. 
GFAP-positive astrocytes are distributed in the neonatal brain with a similar 
regional heterogeneity. Although the GFAP-positive astrocytes showed in 
different pattern during the developmental period, and did not disappear in the 
regional differential pattern at the stage of postnatal, regional allocation of 
reactive astrocyte may be induced by injury. 
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V. CONCLUSION 
 
Consolidating these results, we posit an interpretation for selective striatal 
vulnerability against systemic 3-NP infusion. We suggest that the increased 
ASK1 is linked to regulation of TGF-β secreted in astrocytes, and differential 
C1q expression in neurons triggered by TGF-β1 leads degradation of cortical 
projection and depletion of BDNF in striatal neuron in mice brains systemically 
infused with 3-NP.  
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신경손상에 의한 선택적 선조체 병변형성 기작에서의  
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조 경 주 
 
 
 
본 연구는 유전적 변이와는 관계없이 세포사멸을 유도하는 
3-nitropropionic acid 처치에 의한 신경세포 손상기전이 선조체 
병변 형성에 국한되는 기전을 ASK1에 의한 조절과 관련하여 
살펴보고자 한다. 신경퇴행성질환을 포함하여 뇌의 특정 부위에 
국소적 병변이 형성되는 뇌질환은 일반적 병인론과 함께 neuronal 
loss의 기전 중 하나로서 ubiquitin-proteasome system (UPS)과 
autophagy가 보고되고 있다. 내외부적 요인으로 인해 손상된 
신경세포는 생존을 위해 비정상 독성 단백복합체에 의해 유발되는 
UPS와 autophagy 과정을 처리과정을 시행하고, 최종적으로 
dysfunction synapse 의 synapse loss, impaired autophagy 및 
apoptosis에 의한 neuronal loss과정을 걷게 된다. 이때 3-NP 주입과 
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헌팅톤병은 전신적으로 독성물질에 노출됨에도 불구하고 선조체에만 
국소적으로 병변이 형성되는 특징이 있다.  
이에 본 연구는  
(1) 신경독소인 3-NP에 의해 과발현된 ASK1이 이후 하위단계의 
변화를 통해 뇌의 부위 (striatum vs cortex)에 따라 서로 다른 
세포사멸기작을 유도함으로 3-NP에 의한 감수성 형성에 관여할 
것으로 생각되어 대뇌피질 부위와 선조체 부위에서의 세포사멸 기작 
및 이에 관여하는 물질 및 분자기전을 살펴보고자 하였으며,   
(2) 이를 기반으로 확장된 적용으로서 선조체에 선택적으로 
병변이 생기는 헌팅턴병의 경우에서 병의 진행에 따라 증가하는 
C1q의 분비량 증가여부 및 그 조절 기작에서의 ASK과의 연관성을 
살펴봄으로 선택적 병변형성에서의 ASK1의 역할과 병변형성에 
관여하는 새로운 기전을 살펴보고자 하였다.  
신경퇴행성질환을 포함하여 뇌의 특정 부위에 국소적 병변이 
형성되는 뇌질환은 일반적 병인론과 함께 neuronal loss의 기전 중 
하나로서 ubiquitin-proteasome system (UPS)과 autophagy가 보고되고 
있다. 세포는 기본적으로 잘못 형성된 단백질을 인지하여 그 변형 단
백질을 refold하거나 제거하는 세포간 적절한 네트워크를 통해 건강
한 단백질을 유지하고 있다. 이를 수행하는 세포 내 시스템은 
chaperon 시스템으로 chaperon은 대부분의 비정상 단백질을 처리할 
수 있는 충분한 수용능력을 갖고 있다. 그러나 잠재된 내부적 요인 
혹은 외부적인 손상에 의해 생성된 비정상 단백질이 너무 많아 처리
수용 한계를 넘는다면 비정상 단백질 처리 (clearance)를 위한 또 다
른 시스템을 가동하게 된다. 내외부적 요인으로 인해 손상된 신경세
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포는 생존을 위해 비정상 독성 단백복합체에 의해 유발되는 UPS와 
autophagy 과정을 처리과정을 시행하고, 최종적으로 dysfunction 
synapse 의 synapse loss, impaired autophagy 및 apoptosis에 의한 
neuronal loss과정을 걷게 된다. 이때 3-NP 주입과 헌팅톤병은 전신
적으로 독성물질에 노출됨에도 불구하고 선조체에만 국소적으로 병변
이 형성되는 공통적인 특징이 있다. 이러한 striatal vulnerability
는 striatum에서의 특징적인 변화로 야기되는 cell-autonomous 
mechanism과 striatum이외의 다른 부위에서의 변화에 의해 결과적으
로 specific striatal neuronal loss를 가져오는 non-cell-autonomous 
process로 설명된다. 대표적으로 받아들여지고 있는 설명은 (1) 
cortex로부터의 BDNF 공급 차단에 의한 striatal neuron의 BDNF 결핍
에 의한 striatal degeneration (2) cortex로부터 과분비된 glutamate
로 유발된 excitotoxicity에 의한 selective vulnerability로 요약할 
수 있다.  
Mitogen-Activated Protein Kinase Kinase Kinase (MAPKKK) 
신호전달계의 최상위 단계인자이며, 다양한 세포손상에서 주된 
조절자 역할을 하는 것으로 보고되고 있는 세포고사신호조절 
키나아제(Apoptosis signal-regulating kinase 1, ASK1)는 모든 세포에 
광범위하게 존재하는 155 혹은 170 kD의 단백질이다. ASK1은 MAPKKK 
신호전달계의 최상위 단계인자로서 역할과 더불어 다양한 퇴행성 
뇌질환에서의 세포사멸에 관여한다는 보고들이 발표되고 있으나, 
현재까지는 세포 내 축적된 퇴행성 물질에 의해 유도된 ER stress의 
초기 신호 반응자로서 세포고사 기전에 참여하는 것으로만 발표되고 
있다. 그러나, kinase 도메인을 포함한 3개의 도메인을 포함하고 
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있을 뿐 아니라, 다양한 세포 내 환경에 따라 발현량의 변화를 
나타내는 ASK1의 세포의 운명 조절자로서의 역할은 특정 부위의 
신경세포에서의 조절 역할에 대해서는 거의 보고 되지 않고 있다. 
이에 따라 ASK1의 발현량 조절과 발현량 조절에 따른 분자수준의 
변화는 선택적 세포사멸 기전을 이해하는 데 중요한 역할을 할 
것으로 예상한다. 
한편, innate immune response의 classic pathway의 initiation 
factor인 C1q의 분비량의 변화 및 이로 인한 microglia activation은 
지금까지 중추신경계에서는 발생단계에서의 axon pruning이나, 
synaptic elimination으로 연구가 국한되었으나, 최근 들어 퇴행성 
질환인 알츠하이머병이나, 간질에서 병리기전의 하나로서 연구보고가 
되고 있다. C1q의 발현이 neuroprotective effect를 갖는 것으로 보고
되고는 있으나, 세포 type별, subregion별, damage 정도에 따라 다르
게 작용하고 그 해석도 다양하다. 본 연구는 synapse dysfunction 초
기에 증가되는 C1q를 증상이 시작되는 좋은 prediction marker로서의 
가능성을 연구하며 ASK1가 매개된 조절 기작 여부를 조사함으로 
synaptic loss 또한 보호할 수 있는지 여부를 연구하고자 한다. 그 
동안 많은 연구자들의 노력으로 신경퇴행성질환의 병인 물질 및 뇌세
포 사멸 기작들이 밝혀지고는 있으나, 아직까지 근본적인 치료가 없
을 뿐 아니라, 퇴행성 뇌질환의 특징인 뇌의 특정 지역에서만 국한적
으로 병변이 형성되어 각 신경퇴행성질환마다 특징적인 행동이상 및 
인지기능 이상을 가져오게 되는 선택적 병변형성 기작 및 이에 대한 
예측인자의 발굴을 더욱 절실히 요구되는 연구과제라고 할 수 있다.  
이를 위한 연구수행 결과, 아래와 같은 결과들을 얻을 수 있었
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다. 첫째, ASK1의 발현억제는 헌팅톤 유발 마우스에서 비정상 헌팅틴 
단백질 조각의 핵으로의 이동 및 ER stress 를 감소시켰다. 본 연구
를 통하여 헌팅턴 유발 마우스에서 ASK1 단백질의 양과 ER stress는 
증가 되어있음을 확인할 수 있었으며, 증가된 ASK1은 비정상 헌팅틴
과 결합하여 핵으로의 이동에 영향을 미쳤음을 확인하였다. 결과적으
로 ER stress를 유발한다는 것을 보여주었다. 둘째, 3-nitropropionic 
acid (3-NP)를 이용한 선조체 병변유발 마우스 모델에서 ASK1은 증가
된 활성산소종 (ROS)이 매개하는 선조체 병변을 더욱 악화시킴을 확
인하였다. 3-NP 전신주입은 선조체에 선택적 병변을 형성하며, 3-NP
의 주된 병변기작인 ROS를 감소시킨 SOD1 유전자변형 마우스에서도 
병변을 형성하되 그 크기는 적었다. 과발생한 활성산소종이 많을수록 
산화적 손상 및 ASK1의 단백질량과 그 활성도가 병변이 형성된 선조
체에서 더 많이 관찰됨을 확인하였다. 본 연구를 통해서는 3-NP에 의
해 과발생한 활성산소종이 병변형성에 주된 역할을 하지만, 활성산소
종에 의한 이후 반응에 있어서 ASK1이 중요한 역할을 함을 보였다. 
활성산소종을 제거하는 효소가 과발현된 SOD1 유전자 변형쥐에 ASK1
의 합성한 펩타이드를 주입하면, 동일한 3-NP 주입에도 활성산소종의 
양이 증가한 것이 아님에도 불구하고 심하게 병변이 형성됨을 확인하
였다. 이것은 ROS의 양을 변화시키지 않더라도 ASK1의 단백질 양이 
선조체에서의 신경세포 사멸을 야기할 수 있음을 시사하였다. 그러므
로 본 연구의 결과는 신경퇴행성 질환을 포함한 선조체 병변의 치료
를 위해 활성산소종의 처치 뿐 아니라 이와 더불어 ASK1의 발현량을 
조절함으로 더욱 효과적인 치료가 될 수 있을 것으로 제안할 수 있었
다. 셋째, 3-NP의 전신주입에 의한 선조체 병변형성에 있어서의 ASK1
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의 역할이 신경세포에서 뿐만 아니라, 성상세포에서 분비되는 
TGF-beta를 조절하고, 성상세포에서 분비된 TGF-beta는 신경세포에서
의 선천면역의 complement factor중의 하나인 C1q의 발현 및 분비량
을 조절함으로 선조체 병변형성을 위한 기전에 중요한 역할을 하는 
것을 확인하였다. 3-NP 전신주입에 의한 미토콘드리아 기능이상은 세
포 내 활성산소종을 과발현시켰고,  선조체에서의 BDN혈를 고갈시켰
다. 그런데, 3-NP의 전신주입에 의해 선조체에서 선택적으로 일어나
는 변화 중 성상세포가 선조체 측면에서 강하서 활성화 되는 것을 확
인하였며, 이때 TGF-beta의 유전자 수준이 선조체 부위의 세포에서 
크게 증가할 뿐 아니라, 이와 상응하여 혈액에서의 TGF-beta의 분비
량이 증가함을 확인하였다. 이와 더불어 TGF-beta에 의해 조절 받는
다고 보고된 바 있는 C1q의 유전자 발현 정도와 혈액에서의 분비량 
모두 TGF-beta에 상응하여 변화되는 것을 확인 할 수 있었다. 이에 
ASK1은 성상세포의 TGF-beta의 조절과 연관되어 있으며, 이에 의한 
신경세포에서의 C1q 분비 정도를 변화시킬 수 있은 것으로 확인되었
다. 이것은 대뇌의 특정부위에 병변이 형성되는 신경퇴행성 질환 및 
3-NP에 의한 선조체 병변 형성에 면역인자가 관여되는 또 하나의 가
능성 있는 기전을 제공할 뿐만 아니라, 유전자변이를 갖고 태어난 헌
팅턴병 환자들의 경우, C1q의 혈액내로의 분비량의 변화를 측정함으
로 병증의 증상개시 시기를 예측할 수 있는 표지인자로서의 사용 가
능성 또한 제시할 수 있을 것으로 생각된다.  
 
---------------------------------------------------------------------------------------------------------- 
핵심되는 말: 세포고사신호조절 키나아제, 헌팅톤병, 3-nitropropionic 
acid, brain derived neurotrophic factor, siRNA, superoxide dismutase 
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